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Helios enhances the preferential differentiation of fetal naïve CD4+ T cells into 
regulatory T cells 
Melissa Ng 
 
Abstract 
T cell receptor (TCR) stimulation and cytokine cues drive the differentiation of CD4+ naïve T 
cells into effector T cell populations with distinct pro-inflammatory or regulatory functions. Unlike 
adult naïve T cells, human fetal naïve CD4+ T cells preferentially differentiate into FOXP3+ 
regulatory T (Treg) cells upon TCR activation independent of exogenous cytokine signalling. This 
cell-intrinsic predisposition for Treg differentiation is implicated in generating tolerance in utero; 
however, the underlying mechanisms remain largely unknown. Here, we reveal FOXP3-
independent transcriptional and epigenetic programs shared between fetal naive T cells and 
committed adult Treg cells that are inactive in adult naive T cells. We further demonstrate that 
these transcriptional programs are retained upon Treg cell differentiation only in fetal-derived, but 
not adult-derived induced Treg (iTreg) cells. We identify a subset of Treg-specific enhancers that 
are already active in fetal naive T cells, including two active super-enhancers at Helios, a 
signature thymic Treg gene. Helios is expressed in fetal naive T cells, but not in adult naïve T 
cells, and only fetal iTreg cells maintain Helios expression. Fetal, but not adult iTreg cells, have 
suppressed IL-2 production, which is regulated by Helios in committed Treg cells. CRISPR-Cas9 
ablation of Helios in fetal naive T cells thus resulted in increased IL-2 production by fetal iTreg 
cells. Critically, Helios knockout in fetal naïve T cells impaired their subsequent differentiation 
into Treg cells upon TCR stimulation, reduced the upregulation of immunosuppressive genes 
such as IL10 in fetal iTreg cells, and resulted in the increased upregulation of pro-inflammatory 
genes including IFNG. Subsequently, Helios knockout fetal iTreg cells produced less IL-10 and 
 xi 
more IFNγ cytokines. Taken together, our results indicate a dual role for Helios in enhancing the 
cell-intrinsic predisposition of fetal naïve T cells for Treg differentiation and fine-tuning eventual 
fetal Treg function through transcriptional modulation. The Treg-biased transcriptional and 
epigenetic programs within fetal naive T cells identified here could thus be utilized to engineer 
enhanced iTreg populations from adult naïve T cells for adoptive cellular therapies.  
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CHAPTER 1 - INTRODUCTION
1
1.1 The generation of immune tolerance in early life 
The immune system must constantly maintain balance between two contradictory functions – it 
must achieve a sterilizing, pro-inflammatory response against pathogens defined as non-self, 
while minimizing collateral, non-specific damage towards the host organism. This ability to 
recognize the enormous variety of pathogens that come into contact with the host necessitates 
the generation of a large repertoire of receptors recognizing these non-self entities; however, 
since the receptor generation process is largely governed by probability and is thus non-
specific, the immune system must find a way to prune cells bearing receptors that end up 
recognizing self antigens. Within the T cell arm of the immune system, this is enforced during T 
cell development in the thymus by a mechanism termed “central tolerance”.  Presentation of 
tissue-specific antigens driven by the Aire transcription factor (1, 2), and as well as other self 
antigens presented by thymic dendritic cells (3) and migrating antigen-presenting cells (4), 
weeds out reactive T cells by apoptosis in the process of negative selection.  
 
Notably, the concept of tolerance first arose by experiments on neonatal animals – first through 
studies in 1945 by Ray Owen on dizygotic male-female twin cattle which showed that both twins 
had an equal mix of autologous (self) and allogenic (non-self) erythrocytes that persisted 
throughout life, indicating the generation of tolerance towards the foreign antigens derived from 
the genetically distinct twin (5). Additional studies also emerged supporting the concept of 
tolerance generated in early life by skin graft transplant studies between fraternal cattle twins, 
which again showed the absence of rejection between two genetically dissimilar animals 
(6).Further dissection in mice and chickens revealed that this phenomenon could also be 
recreated in strains that were of completely different genetic backgrounds, but only if antigenic 
stimulation was provided during fetal life (7).These findings actively kick-started the discoveries 
leading to the formulation of the theory of central tolerance – that tolerance was actively 
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generated in response to antigen exposure by the elimination of cell “clones” carrying a receptor 
that recognized the particular antigen.     
 
Interestingly, it has been perhaps overlooked that the tolerance obtained in Billingham’s and 
Medawar’s skin graft experiments is not fully penetrant, since the only three out of the five 
transplant grafts on fetal mice were actually tolerated. Furthermore, tolerance to the graft in 
mice could be revoked easily if they were re-implanted with lymph nodes from the same strain of 
mice that were actively immunized against the donor mice (i.e. a crude transfer of antigen-
experienced memory and effector cells!) (7). On hindsight, it seems that these experiments were 
maybe more suggestive of a second mechanism of tolerance – that of dominant tolerance being 
enforced by a cell population that is actively suppressing effector cell responses, which could be 
overturned by overwhelming the population with antigen-experienced cells. Within the T cell 
compartment, the best-studied population is CD4+CD25hiFOXP3hi regulatory T (Treg) cells, which 
were first described as CD25hi suppressor cells in 1995 by Sakaguchi (8), and were jointly 
described as FOXP3+ in 2003 by three independent groups (9-11). In another nod to the 
importance of dominant tolerance in early life, inklings that such a cell population was present 
within the T cell compartment was borne from observations in thymectomy of 3 day old mice 
that resulted in autoimmune disease (12). Full ablation of the Treg population in mice by genetic 
knockout of FOXP3, the master transcription factor regulating Treg development and function or 
by transfer of only CD25lo T cells into an athymic nude mouse, then resulted in early-onset fatal 
autoimmunity within a month (summarized in (13)).  
 
Similarly, the loss of FOXP3 manifests within human as the disease IPEX (Immune 
dysregulation, polyendocrinopathy, enteropathy, X-linked), where mutations at the FOXP3 locus 
lead to an absent or non-functional Treg population, leading to death of the neonate without 
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hematopoietic stem cell transplant (11, 14, 15). There has been growing recognition that IPEX 
can initiate in utero, and the onset of autoimmunity coincides with the emergence of T cells in 
the peripheral lymphoid organs in the second trimester. This suggests that active Treg cell 
mediated tolerance is required as early as the second trimester in humans, and the loss of 
tolerance leads to pro-inflammatory responses that trigger adverse outcomes such as 
miscarriage and preterm birth (16-20).  
 
1.2 Regulatory T cells – differentiation and function 
Treg cells have been delineated into two distinct populations based on their differentiation origin 
– thymic or peripheral. Thymic Treg (tTreg) cells have been proposed to be derived in the thymus 
from CD4 single positive (SP) thymocytes bearing T cell receptors that have a strong affinity for 
self-antigens that straddle a middle ground for TCR signaling strength between negative and 
positive selection thresholds. By directing self-reactive thymocytes away from deletion towards 
a Treg cell fate, this allows the immune system to generate dominant tolerance towards self-
antigens (summarized in (21)). In contrast, peripheral Treg (pTreg) cells are generally assumed to 
have differentiated from CD4+ naïve T cells after antigen stimulation that is received 
simultaneously with specific signaling cues from cytokines such as TGFβ, and small molecules 
such as retinoic acid (RA) that are produced locally in peripheral organs such as the gut (22-24). 
Signaling by TGFβ is especially crucial for pTreg over tTreg generation, since T cell specific 
ablation of TGFβ1 (25) and TGFβRII (26, 27) results in the paucity of the former and not the 
latter. Given that activation usually occurs to non-self antigen, this is thought to be a mechanism 
by which dominant tolerance to harmless non-self antigens derived from environmental, food or 
commensal microbial origins is generated. Regardless of their developmental origins, both Treg 
subsets are characterized by constitutive expression of FOXP3, which is maintained by 
epigenetic and transcriptional mechanisms at the FOXP3 gene locus. One such epigenetic 
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mechanism is DNA demethylation at Treg-specific demethylated region (TSDR) the within 
conserved non-coding sequence (CNS) 2 region in the FOXP3 gene, which is required for 
continued stability of the Treg phenotype. Acquisition of TSDR demethylation occurs 
concurrently, but independently of FOXP3 expression (28). Deletion of the CNS2 in the Treg 
population led to the gradual loss of FOXP3 expression over time, as seen in the reduced 
percentages of Treg cells in the peripheral lymphoid organs in old but not young mice (29). This 
was linked to proliferation-induced instability as FOXP3ΔCNS2-gfp Treg cells lost FOXP3 
progressively over rounds of division induced by TCR signaling in vitro (29).  
 
Additional changes in the enhancer landscape also precede the upregulation of FOXP3 and 
commitment to the Treg phenotype, and this has been elucidated most clearly in thymic Treg 
precursors (30). These changes are governed by the acquisition of permissive histone 
modifications such as acetylation at lysine 27 at histone 3 (H3K27ac), which increase the 
accessibility of the underlying histone-wrapped DNA to allow the recruitment of transcriptional 
machinery to the associated gene to initiate gene transcription. By collapsing individual 
enhancer regions into large stitched super-enhancer (SE) regions, SEs identified to be specific 
to Treg and not conventional T cells were found to be associated with genes regulating Treg 
function and commitment such as FOXP3, IL2RA and CTLA4 (30). These Treg SE regions 
gained permissive histone marks progressively throughout thymic Treg differentiation before 
FOXP3 upregulation and final commitment into tTreg cells (30). The genome organizer SATB1 
(Special AT-rich sequence binding protein 1) plays a key role in facilitating enhancer activation 
at closed Treg SE. Deletion of SATB1 within CD4 SP thymocytes resulted in the depletion of 
thymic Treg populations and this was specifically attributed to the inability of thymic Treg 
progenitors to acquire permissive histone marks at Treg SE that impaired their subsequent 
differentiation into Treg cells (30). Given that the pTreg population also show a similar enhancer 
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landscape and demethylation patterns (28, 30, 31), it seems likely that similar mechanisms also 
govern their differentiation from naïve T cells; however the upstream mediators and molecular 
pathways that regulate this have yet to be elucidated.  
 
Although that Treg cells comprise such a small fraction of the total population in mice and 
humans (naturally about 5% in human adult peripheral blood), they exert outsized effects on 
dominant immune tolerance given the fatal immunopathology that results when the entire 
population is ablated. Treg cells have been proposed to mediate suppression of a large variety of 
cell types (summarized in (32)), and this is likely due to their ability to mediate “bystander” 
suppression even after antigen-specific activation through the use of non-specific suppressive 
mechanisms. Mechanisms utilized include (1) the secretion of immunosuppressive cytokines 
such as IL-10, TGFβ and IL-35, (2) preferential consumption, and thus deprivation of survival 
factors such as IL-2 to conventional T cells, (3) cell-contact dependent suppression via cell 
surface molecules such as CTLA-4 and (4) the functional modulation of antigen presentation 
capability of antigen presenting cells (APCs) to suppress their subsequent activation of antigen-
specific conventional T cells. (summarized in reviews (33, 34)). Given the potent and 
multifactorial effects of immunosuppression mediated by Treg cells, there has been great interest 
in their generation in vitro for use in clinical settings of autoimmunity and inflammation. Early 
studies found that a FOXP3hiCD25hi induced Treg (iTreg) population can be generated in vitro from 
naïve T cells in both mice and humans through the use of TCR stimulation together with TGFβ 
(35, 36). However this conversion is only observed for a subset of human naïve T cells and not 
the full population, which presents a problem of obtaining a phenotypically pure population of 
FOXP3hiCD25hi iTreg (37). Additional, human iTreg cells generated from adult naïve T cells fail to 
repress the IL2 and IFNG locus, leading to re-stimulation induced production of IL-2 and IFNγ 
(37). Lastly, iTreg cells fail to acquire Treg-specific demethylation patterns at FOXP3 and other 
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well-defined Treg gene regions such as GITR and CTLA4 (28), which resulted in the failure of 
iTreg cells to retain the Treg phenotype upon transfer in vivo, and reversion into a effector 
phenotype (38). As such, it is clear that TGFβ driven in vitro Treg differentiation does not fully 
recapitulate Treg differentiation in vivo, and further characterization of upstream factors that drive 
Treg commitment and stability in vivo is greatly needed.  
 
1.3 Aims of this study 
Consistent with the need for Treg mediated tolerance in fetal development, we observe that Treg 
cells comprise a larger percentage of the CD4+ T cell population in secondary lymphoid tissues 
compared to adults, ranging from 10% up to 20% (39-41). However, thymic Treg percentages 
within the fetal and postnatal thymus were not found to be different (40), excluding the possibility 
that increased tTreg output could account for the increased Treg cell frequency in the periphery. 
We have also shown that a larger proportion of fetal naïve T cells differentiate in vitro into Treg 
cells upon antigenic stimulation with APCs (41), or TCR stimulation with TGFβ (42). 
Interestingly, an average of about 20-40% of fetal naïve T cells can differentiate into Treg cells in 
vitro with TCR stimulation in the absence of TGFβ supplementation (42), which is unusual given 
that TGFβ is thought to be necessary for inducing FOXP3 expression and Treg differentiation in 
vitro. This unique ability for increased Treg differentiation in the absence of TGFβ suggest that 
cell-intrinsic mechanisms predispose fetal naïve T cells towards the Treg cell fate, and implies 
that conversion from naïve T cells in the periphery might be responsible for the increased Treg 
proportions observed.  
 
The aims of this work were to identify the molecular mechanisms underpinning preferential Treg 
differentiation; specifically, whether the transcriptional and epigenetic landscape in fetal naïve T 
cells were analogous to that of thymic Treg progenitors, thus poising the fetal naïve T cell for Treg 
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differentiation. We predicted that this approach would result in the identification of candidate 
genes that would allow us to more carefully dissect the pathways leading to fetal Treg 
differentiation. Lastly, this approach would provide a valuable resource to the community by 
identifying cell-intrinsic factors that could contribute to strategies to induce Treg populations in 
vitro that more closely resemble Treg populations in vivo in terms of stability and function.  
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CHAPTER 2 - Helios predisposes fetal naïve CD4+ T cells towards regulatory T cell 
differentiation 
 
Material for this chapter was modified from a manuscript currently in revision: 
Ng MSF, Roth TL, Mendoza VF, Marson A, Burt TD. Helios predisposes human fetal CD4+ 
naïve T cells towards regulatory T cell differentiation. 2019 (in revision) 
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2.1 ABSTRACT 
T cell receptor (TCR) stimulation and cytokine cues drive differentiation of CD4+ naïve T cells 
into effector T cell populations with distinct pro-inflammatory or regulatory functions. Unlike adult 
naïve T cells, human fetal naïve CD4+ T cells preferentially differentiate into FOXP3+ regulatory 
T (Treg) cells upon TCR activation independent of exogenous cytokine signalling. This cell-
intrinsic predisposition for Treg differentiation is crucial for generating tolerance in utero; 
however, the underlying mechanisms remain largely unknown. Here, we identify epigenetic and 
transcriptional programs shared between fetal naive T and committed Treg cells that are inactive 
in adult naive T cells, and that only fetal-derived induced Treg (iTreg) cells retain these 
transcriptional programs. We show that a subset of Treg-specific enhancers are accessible in 
fetal naive T cells, including two active super-enhancers at Helios. Helios is expressed in fetal 
naive T cells, but not in adult naïve T cells, and only fetal iTreg cells maintain Helios expression. 
CRISPR-Cas9 ablation of Helios in fetal naïve T cells impaired their differentiation into Treg cells 
upon TCR stimulation, reduced expression of genes in fetal iTreg cells associated with 
immunosuppressive function such as IL10, and increased expression of pro-inflammatory genes 
including IFNG. Subsequently, Helios knockout fetal iTreg cells had reduced IL-10 and increased 
IFNγ cytokine production. Together, our results reveal an important role for Helios in enhancing 
preferential fetal Treg differentiation and fine-tuning eventual Treg function. The Treg-biased 
programs identified within fetal naive T cells could potentially be utilized to engineer enhanced 
iTreg populations for adoptive cellular therapies. 
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2.2 INTRODUCTION 
The adaptive immune system must generate immunotolerance in order to prevent or resolve 
pro-inflammatory responses that can cause host damage (24, 43, 44), while still permitting 
functional effector responses for host defense against pathogens (45, 46). A primary 
mechanism by which this flexibility is achieved is via the capacity of CD4+ naive T cells to 
differentiate into multiple distinct specialized T helper subsets with either pro-inflammatory or 
immunosuppressive functions. The presence of polarizing cytokines within their immediate 
environment determine the eventual helper T (Th) cell fate by triggering the expression and/or 
activation of master transcription factors that enact lineage specific transcriptional programs 
(47). Signaling by transforming growth factor β (TGFβ) promotes the induction of FOXP3 (35, 
36, 48), which is the master transcription factor required for the differentiation of naïve T cells 
into immunosuppressive regulatory T (Treg) cells.  
 
Mutations of the FOXP3 gene leading to the complete absence or dysfunction of Treg cells 
results in the loss of Treg-mediated immunotolerance, and triggers fatal, early onset multi-organ 
autoimmunity in both mice and humans (9, 11, 14, 15, 49, 50). Autoimmunity resulting from the 
loss of FOXP3+ Treg cell-mediated tolerance in humans, defined as the disease IPEX (Immune 
dysregulation, polyendocrinopathy, enteropathy, X-linked), can manifest within the fetus in utero 
and result in miscarriage, preterm birth, and ultimately neonatal death without hematopoietic 
stem cell transplant (16-20). The initiation of autoimmunity in IPEX coincides with the 
emergence of T cells in the second trimester of human development, suggesting that Treg cell-
mediated peripheral tolerance is required during fetal development (51, 52). This is supported 
by the presence of an abundant population of fetal Treg cells in the secondary lymphoid tissues, 
which comprise a larger percentage of the total CD4+ T cell population compared to adults (39-
41). However, thymic Treg cell frequencies in fetal and infant thymus are not significantly different 
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(40), indicating that increased thymic output is not responsible for the increased frequency of 
fetal Treg cells. Fetal naive T cells, unlike their adult counterparts, preferentially differentiate into 
functional Treg cells upon antigenic encounter, which include non-inherited maternal allo-
antigens (i.e. NIMAs) on maternal antigen presenting cells (40). These findings suggest that the 
abundance of fetal Treg cells observed in fetal lymphoid tissues is due to peripheral conversion 
from naïve T cells. This propensity for Treg differentiation is retained in vitro, as a high frequency 
of fetal naïve T cells differentiate into FOXP3+ Treg cells upon TCR activation even in the 
absence of exogenous TGFβ (42). The unique capability of fetal naïve T cells initiate Treg 
differentiation in the absence of exogenous TGFβ suggests that this ability is cell-intrinsic; 
however, the molecular mechanisms that underlie this predisposition are largely unknown.  
 
Chromatin changes are also implicated in driving the final effector phenotype and function of 
differentiated T cells, defined by increases in chromatin accessibility of active lineage-specific 
genes, and the silencing of genes associated with other effector lineages (53, 54). In thymic 
and peripheral Treg cells, the accumulation of permissive/active histone marks and DNA 
demethylation at Treg associated genes such as IL2RA (i.e., CD25), CTLA4, IKZF2 (i.e., Helios), 
and IKZF4 (i.e., Eos) (28, 30) must be acquired for commitment to and maintenance of the Treg 
phenotype (28-30, 55). This Treg-chromatin landscape is acquired within developing thymic Treg-
cell precursors before FOXP3 protein expression (30), suggesting that a Treg-specific 
epigenome may be responsible for initiating and promoting the expression of FOXP3. 
Additionally, other key genes associated with the Treg epigenome, such as Helios, are expressed 
independently of FOXP3 expression (28, 30, 56), and can direct the partial acquisition of the 
Treg-specific transcriptional signature when over-expressed in FOXP3-CD4+ T cells (57). We 
therefore hypothesized that fetal naïve T cells might already possess a partial Treg-specific 
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epigenetic and transcriptional signature that predisposes them for differentiation towards the Treg 
cell fate even without exogenous TGFβ signaling.  
 
Here, we interrogated the transcriptional and chromatin landscape of fetal and adult naïve and 
Treg cells, and indeed discovered that components of the Treg gene regulatory program are 
already activated in fetal naïve T cells, but not in adult naïve T cells. We show the partial Treg-
specific gene signature detected at steady state in fetal naïve T cells is retained only fetal-
derived, but not adult induced Treg cells. We further identify two Treg-specific super-enhancers 
(SEs) associated with the Helios locus that are active in fetal naïve, but not adult naïve T cells. 
Correspondingly, protein expression of Helios was increased in fetal naive T cells over adult 
naive T cells. Only induced Treg (iTreg) cells generated from fetal naïve T cells in vitro retained 
Helios expression and were characterized by repression of IL-2 production; both of which were 
not observed in adult iTreg cells. CRISPR-mediated ablation of Helios in fetal naive T cells 
impaired their cell-intrinsic ability to differentiate into Treg cells in the absence of exogenous 
TGFβ. Analysis of the transcriptome in Helios knockout iTreg cells revealed that Helios enhanced 
the upregulation of Treg-specific genes (e.g., IL10) and mediated the repression of pro-
inflammatory genes involved in Th effector differentiation and function (e.g., IFNG). Helios 
ablation in fetal iTreg cells subsequently resulted in decreased IL-10 cytokine production 
concurrent with increased IFNγ and IL-2. Given that Helios has been previously characterized to 
be a gene specific to thymic Treg cells, our data reveal a new role for Helios as part of a pre-
existing epigenetic and transcriptional program within human fetal naïve T cells that lowers the 
threshold for Treg differentiation and functional commitment. Taken together, we thus identify a 
TGFβ-independent mechanism unique to fetal naïve T cells that favors their differentiation into 
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Treg cells, and may contribute insights into better engineering Treg cells in vitro from naïve T cells 
for use in immunotherapy. 
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2.3 RESULTS 
2.3.1 Human fetal naïve T cells express a partial Treg transcriptome. 
Given that fetal naïve T cells preferentially differentiate into Treg cells upon TCR stimulation 
alone (42), we first asked if fetal naïve T cells shared elements of their transcriptome with Treg 
cells that could predispose them towards the Treg lineage. We performed RNA sequencing 
(RNAseq) on sorted fetal and adult CD4+ naïve and Treg cells (for sort gating strategy and purity 
confirmation, see Fig. 1). Principal component analysis (PCA) revealed that fetal and adult 
populations first segregated by cell origin (PC1, fetal or adult) before cell phenotype (PC2, naïve 
versus Treg, Fig. 3A). PC2 scores for fetal naïve samples were intermediate to adult naïve and 
Treg samples (Fig. 3A), suggestive of intermediate expression of Treg-specific genes in fetal naïve 
T cells. In order to test this hypothesis, we first defined a Treg-specific transcriptional signature 
by identifying genes differentially expressed in both fetal and adult Treg cells relative to adult 
naïve T cells based on a false discovery rate cut-off of FDR<0.05 and log 2 fold change (log2FC) 
increase in expression of 1.5 (Fig. 2, Table 1). Fetal naïve T cells possessed intermediate 
upregulation/downregulation (Fig. 3B) across genes upregulated/downregulated in our Treg-
specific transcriptional signature. More specifically, relative to adult naïve T cells, fetal naïve T 
cells had 88 Treg-upregulated and 42 Treg-downregulated genes within the Treg-specific 
transcriptome (Fig. 1C). Using k-means clustering, we defined four different clusters within the 
full Treg-specific transcriptome (Fig. 3B, Table 1) – two of which corresponded to all Treg-
upregulated genes (Cluster 1.1, 1.2), while the other two clusters contained all Treg-
downregulated genes (Cluster 1.3, 1.4). Within Treg-upregulated genes, fetal naïve T cells did 
not share expression of canonical Treg genes such as FOXP3, IL2RA and CTLA-4 with adult and 
fetal Treg cells (Cluster 1.1, Fig. 3B). Instead, fetal naïve T cells had increased expression of 
Treg-upregulated genes associated with Cluster 1.2 (Fig. 3B), which contained genes previously 
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associated with Treg function such as CCR4 (58, 59) and KLF10 (60-62), as well as the 
transcription factors IKZF2 (Helios) (63-65) and IKZF4 (Eos) (57, 66) (Cluster 2, Fig. 3B,1C) 
which are transcribed independently of FOXP3 expression in mice (28, 56, 67). Similarly, fetal 
naïve T cells and both the Treg cell populations shared similar downregulation of a subset of 
genes such as TSHZ2 and SERPINB6 (68-70) (Cluster 1.3, Fig. 3B) previously characterized 
as being downregulated in Treg cells. Taken together, our data suggest that although both fetal 
and adult naïve T cells share expression of genes corresponding to their naïve T cell phenotype 
such as TCF7 and IL7R (Cluster 1.4, Fig. 3B), fetal naïve T cells are already transcriptionally 
primed at steady state to differentiate into Treg cells. The presence of a partial Treg-specific 
signature in fetal naïve T cells could then help potentiate Treg differentiation upon the receipt of 
TCR signaling, consistent with the lowered threshold and greater propensity for these cells 
towards Treg differentiation (40, 42).  
 
2.3.2 Fetal-derived induced Treg (iTreg) cells maintain differential expression of the partial Treg-
specific transcriptome present in fetal naïve T cells at the steady state.  
We next asked if the partial Treg-specific transcriptome detected in fetal naïve T cells would 
remain differentially expressed in fetal iTreg cells, or whether adult iTreg cells eventually acquire 
the Treg-specific transcriptome after in vitro differentiation. To assess this, we performed 
RNAseq on fetal and adult iTreg cells that underwent differentiation with TCR stimulation in 
media supplemented with interleukin 2 (IL-2-iTreg) alone or additionally supplemented with TGFβ 
(TGFβ-iTreg). PCA revealed that PC1 still segregated iTreg populations by cell origin (fetal or 
adult), after which populations separated by the stimulus received during differentiation 
(absence/presence of TGFβ, PC2, Figure 2A). This indicated that fetal-derived iTreg cells were 
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still transcriptionally different from adult-derived iTreg cells, although the addition of TGFβ was 
sufficient to drive differential expression of a shared set of genes. We then evaluated all 
differentially expressed genes (FDR<0.05 and log2FC>1.5) across all iTreg populations (Fig. 4B), 
and defined six clusters using k-means clustering (Table 2). Both populations of fetal and adult 
TGFβ-iTreg cells upregulated expression of two gene clusters (Cluster 2.1& 2.2, Fig. 4B, Fig. 
5A), and downregulated expression of one gene cluster (Cluster 2.6, Fig.4B, Fig. 5A). This 
included Treg-specific genes known to be upregulated with TGFβ signaling such as FOXP3 and 
IKZF4 (71), as well genes potentially implicated in Treg differentiation and function such as 
SEMA4A (72), LTBP1, LTBP4 (73) and LGALS3 (74, 75). However, although adult TGFβ-iTreg 
cells acquire expression of several Treg-specific genes, only fetal iTreg cells had increased 
expression of Treg-specific genes associated with Cluster 2.3 (Fig. 4B, Fig. 5A) regardless of 
stimulation condition, including genes such as IKZF2, DUSP4, TOX and RGS1 that already had 
increased expression in ex vivo fetal naïve T cells (Fig. 1C).  Decreased transcription of pro-
inflammatory transcripts such as IFNG, IL2, GZMB and IRF7 (Cluster 2.5, Fig. 4B, Fig. 5A), and 
increased expression of genes involved in Treg cell suppressive function such as IL10 (Cluster 
2.3, Fig. 4B) were only observed in fetal, but not adult, iTreg cells. This suggested that 
qualitatively, fetal iTreg cells, especially TGFβ-iTreg cells, have a transcriptome more reflective of 
ex vivo Treg populations relative to adult iTreg cells. We thus utilized Gene Set Enrichment 
Analysis (GSEA) to independently compare the transcriptomes of fetal or adult-derived iTreg 
populations against published gene sets comparing Treg and conventional T cell populations that 
also underwent TCR and cytokine stimulated activation in vitro (56, 76) (Fig. 5B, Table 3). In 
comparison to adult iTreg cells, fetal iTreg cells differentiated in both stimulation conditions had 
enrichment in genes upregulated in activated Treg populations (Fig. 4B), as well as continued 
enrichment of the partial Treg-specific signature as defined by Cluster 1.2 and 1.3 (Fig. 3B, 2C, 
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left, Fig. 5C). Exogenous TGFβ signaling during Treg differentiation then resulted in the 
enrichment of Cluster 1.1 and depletion of Cluster 1.4 genes within fetal TGFβ-iTreg but not adult 
TGFβ-iTreg cells (Fig. 4C, right, Fig. 5D). Our data thus show that differentiating fetal naïve T 
cells, independently of exogenous TGFβ, retain increased expression of the partial Treg-specific 
transcriptional signature detected in ex vivo naïve T cells. Furthermore, the expression of these 
genes do not reach the same levels in adult iTreg cells, suggesting that upstream mechanisms 
might be responsible for driving the transcriptional differences that favor Treg differentiation in 
fetal naïve T cells. 
 
2.3.3 Fetal iTreg cells have increased sensitivity to TGFβ signaling 
In addition to increased expression of genes associated with Treg function, fetal IL-2-iTreg cells 
strongly upregulated a gene cluster which included key genes associated with TGFβ 
sequestration and downstream signaling – including SMAD1, TGFBR3, LRRC32 (37, 77) and 
LIN28B (42) (Cluster 2.4, Fig. 4B, Fig. 6A). Additionally, increased expression of Lin28b protein 
exclusively in fetal naïve T cells results in increased expression of TGFBR1, TGFBR3, SMAD2, 
as well as increased phosphorylation of SMAD2/3 (42). GARP (LRRC32) is expressed highly on 
the cell surface of activated Treg cells and captures the inactive TGFβ bound to the latency-
associated peptide (LAP) (37, 78). This reservoir of cell-surface associated TGFβ is further 
implicated in the maintenance of oral tolerance in mice (77), as well as in the induction of 
FOXP3 in naïve T cells co-cultured with GARP+Treg cells (37). Here we demonstrate that fetal 
but not adult iTreg cells highly expressed GARP (Fig. 6B) and LAP in a linear fashion (Fig. 6C). 
Furthermore, fetal iTreg, but not adult iTreg cells have increased transcription of ITGB8 (Cluster 3, 
Fig. 4B), the beta chain for the integrin αvβ8 that processes and releases bioactive TGFβ1 from 
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LAP (77). Since fetal iTreg cells have increased cell surface-associated TGFβ and the 
machinery to mediate its potential release, we tested whether blockade of TGFβ1 with TGFβ-
neutralizing antibodies resulted in decreased fetal Treg differentiation in response to TCR 
stimulation alone. As hypothesized, fetal Treg induction was blunted in the setting of TGFβ 
blockade (Fig. 6D, E). However, fetal naïve T cells still retained an increased ability for Treg 
differentiation over adult naïve T cells at both blocking antibody concentrations, as well as when 
exogenous bioactive TGFβ was added (Fig. 6D,E). Hence, although active TGFβ1 biogenesis 
may contribute to fetal iTreg differentiation in the absence of exogenous TGFβ, additional 
upstream mechanisms are responsible for driving enhanced fetal Treg differentiation in vitro.  
 
2.3.4 Fetal naïve T cells share a partial epigenetic landscape with adult Treg cells  
Given that fetal naïve T cells already express a partial Treg-specific signature, we next assessed 
if we could also detect the presence of permissive epigenetic marks in fetal naïve T cells that 
could further drive the predisposition towards more robust Treg cell differentiation. In order to 
identify these chromatin features, we used Assay for Transposase-Accessible Chromatin 
followed by sequencing (ATACseq) and H3K27ac chromatin immunoprecipitation sequencing 
(ChIPseq) to compare regions of open and active chromatin in adult Treg cells relative to fetal 
and adult naïve T cells.  Super-enhancers (SEs) and typical transcriptional enhancers (TEs) 
were classified using the ROSE algorithm (79, 80), and PCA was performed across enhancers 
identified in all samples.  Cell origin (fetal versus adult) was the primary source of variance 
(PC1) in both ATACseq (Fig. 8A) and H3K27ac ChIPseq (Fig. 8B), and together with cell 
phenotype (naïve or Treg), largely accounted for differences in the epigenome across all three 
populations. However, fetal naïve and adult Treg cell samples clustered together across the 
second source of variance (PC2) in both datasets (Fig. 8A,B). This suggested that, in addition to 
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expression of a partial Treg-specific transcriptome, fetal naïve T cells share a small subset of 
open and active Treg-specific enhancers with adult Treg cells. 
We first independently defined enhancers differentially enriched for ATAC (Fig. 7A) or H3K27ac 
(Fig. 7B) signal in adult Treg cells relative to adult naïve T cells (FDR<0.05; expression fold 
change>1.5). Enhancers classified as having both increased H3K27ac and ATAC signals in 
adult Treg cells relative to adult naïve T cells were termed Treg-accessible enhancers (Fig. 7C, 
Table 4), while common enhancers were defined as having no difference in enrichment of both 
signals (Fig. 7C). Treg-inaccessible enhancers with decreased signals were similarly defined 
(Table 5). We then assessed if any Treg-accessible enhancers that were enriched in fetal naïve T 
cells relative to adult naïve T cells. We found that fetal naive T cells had increased ATAC signal 
at 38.8% (933/2405, Fig. 7D) and increased H3K27ac signal at 4.6% (110/2405, Fig. 7E) of 
enhancers within the Treg-accessible enhancer signature (Fig. 8C). Treg-accessible enhancers 
preferentially enriched in fetal naïve T cells (Table 4) were annotated to genes previously 
described to be part of the Treg-specific epigenome, such as IKZF2 (i.e., Helios), IKZF4 (i.e., 
Eos) and RXRA (i.e., retinoic receptor RXR-alpha) (28, 30, 55). Similarly, 23.1% (426/1837, 
Fig. D) and 14% (258/1837, Fig. 7E) of Treg-inaccessible enhancers also had decreased ATAC 
and H3K27ac signal, respectively, in fetal naive T cells (Fig. 8C).  
 
Since fetal naïve T cells demonstrated intermediate expression across the full Treg-specific 
transcriptional signature, we assessed if fetal naïve T cells also had intermediate enrichment of 
open and active chromatin across the full Treg-accessible/inaccessible enhancer signature. Fetal 
naïve T cells had increased enrichment of open chromatin across all Treg-accessible enhancers 
relative to adult naïve T cells (left, Fig. 7F), and decreased enrichment of open chromatin across 
all Treg-inaccessible enhancers (right, Fig. 7F). However, we did not detect similar 
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enrichment/depletion for H3K27ac across the Treg-accessible or Treg-inaccessible enhancer 
signature (Fig. 7G ), consistent with the lower number of Treg-accessible/inaccessible enhancers 
identified with increased/decreased H3K27ac signal in fetal naïve T cells (Fig. 8C). Taken 
together, our data suggests that fetal naïve T cells at steady state are poised for Treg 
differentiation by the partial acquisition of a Treg epigenomic landscape characterized by 
increased chromatin accessibility at more than a third of total Treg-accessible enhancers relative 
to adult naïve T cells. Given that chromatin accessibility may precede H3K27ac deposition (81), 
acquisition of the Treg epigenetic signature within fetal naïve T cells could occur in a stepwise 
fashion where full enhancer activation via H3K27ac deposition is acquired with the triggering of 
Treg cell differentiation.  
 
In support of this hypothesis, we evaluated transcription factor motif enrichment within all Treg-
accessible peaks shared between in fetal naïve and committed adult Treg cells (defined in a 
similar manner as TEs/SEs). Peak calls were utilized to minimize false positives stemming from 
the broadness of SE regions. Fetal naïve T cells had minimal enrichment of Treg-accessible 
H3K27ac peaks, but had increased chromatin accessibility at a third of all Treg-accessible ATAC 
peaks (Fig. 9A). These shared Treg-accessible peaks had a large enrichment of binding motifs 
for the AP-1 complex (Fig. 9B) and RUNX1 (Fig. 9C, Table 6), which are downstream of TCR 
signaling and play critical roles as transcriptional regulators of the FOXP3 locus and as co-
factors for FOXP3 (82). We also detected a smaller subset of peaks that had enrichment of 
binding motifs for STAT5 (Fig. 9D) and SMAD2/3 (Fig. 9E). This suggests that increased 
chromatin accessibility could potentially synergize with enhancer activation and faster 
transcription of genes underlying STAT5 and SMAD2/3 binding sites with IL-2 and TGFβ 
signaling during fetal Treg differentiation. Lastly, we examined differentially enriched Treg-
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accessible peaks in fetal naïve T cells for the presence of FOXP3 binding sites previously 
identified in human Treg cells (82). We show that only 5% (116/2213) of shared Treg-accessible 
peaks with increased chromatin accessibility have FOXP3 binding sites (Fig. 9F). Taken 
together, we further illustrate that increased chromatin accessibility within fetal naïve T cells is 
largely poised to synergize with TCR and cytokine signaling cues, and to a smaller extent, 
FOXP3 upregulation, to drive their preferential differentiation into Treg cells.  
 
2.3.5 Fetal naïve T cells have increased open and active chromatin at two Treg-accessible 
superenhancers associated with Helios 
SE regions nucleate the assembly of transcription factors to drive gene expression associated 
with cell lineage commitment (79, 80, 83). Highly ranked SEs shared across fetal naïve, adult 
naïve, and adult Treg samples thus corresponded to genes commonly associated with global T 
cell development and function such as BCL11B (84) and ETS1 (85) (Fig. 10A, Table 7). 
Because increased accessibility at Treg SE regions in murine thymic Treg progenitors precedes 
FOXP3 upregulation and commitment to the Treg lineage (30), we asked if increased 
accessibility at Treg-accessible SEs in fetal naïve T cells could contribute to the priming of fetal 
naïve T cells for Treg differentiation. Out of the 121 Treg-accessible SEs identified, many were 
proximal to canonical Treg genes including FOXP3, IL2RA, CTLA4, TNFRSF4 (i.e., TNF receptor 
superfamily member 4) and IKZF2 (Fig. 8D) as previously described in mice (30). Globally, fetal 
naïve T cells did not have greater accessible chromatin or H3K27ac enrichment at all Treg-
accessible SEs compared to adult naïve T cells (Fig. 10B). This suggested that unlike thymic 
Treg progenitors, fetal naive T cells might acquire active enhancer marks at the full Treg-
accessible SE signature only after Treg differentiation. Since we did not observe enrichment of 
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open or active chromatin across the full Treg-accessible SE signature, we wondered if any SEs 
independently classified by ROSE, and preferentially enriched within fetal naïve T cells relative 
to adult naïve T cells, were proximal to genes associated with Treg accessible-SEs, since their 
presence would have been masked by the global analysis. Most genes associated with Treg 
accessible-SEs did not have enrichment of H3K27ac signal that met the SE cut-off in both fetal 
and adult naïve T cells (Fig. 8E). One exception was the transcription factor IKZF2 (i.e., Helios), 
which was unique to fetal naïve T cells (left, Fig. 8E), and previously identified to be one of the 
first Treg-SEs to acquire permissive epigenetic marks in murine thymic Treg progenitors (30). 
Adult naïve T cells had independent SE classification for one gene, ZC3H12D (right, Fig. 8E); 
however, its association with Treg cell function is yet unknown.  
 
Cell-specific SE regions are typically found proximal to genes encoding transcription factors that 
play key roles in cell identity by controlling the transcription of lineage-specific transcriptional 
programs (30, 79). We next expanded our analysis to evaluate if any Treg-accessible SEs 
defined within adult Treg cells had increased enrichment of either ATAC or H3K27ac signal in 
fetal naive T cells relative to adult naive T cells (Fig. 8C), and were also associated with known 
transcription factors. We identified five Treg-accessible SEs associated with four different 
transcription factors with increased ATAC signal (Fig. 8F), of which only two Treg-accessible SEs 
were also differentially enriched for H3K27ac (Figure 3G). Both of these active, H3K27ac-
marked Treg-accessible SEs were located in the intragenic and upstream regions within the 
Helios locus (Figure 4A), indicating that active expression of Helios might already be present in 
fetal naïve T cells. Helios was identified as a major contributor to PC2 (Fig. 11B) by RNAseq, 
which segregated cells by naïve or Treg phenotypes, and was among the significant Treg-
upregulated genes with increased RNA transcription in fetal naïve T cells relative to adult naïve 
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T cells (Fig. 1C, Fig. 11C). Since a SE was also independently identified at the Helios locus in 
fetal naïve T cells (Fig. 8E), and enriched permissive epigenetic marks and transcription at the 
Helios gene locus regulate Treg phenotype and function independent of FOXP3 expression in 
mice (28, 56, 86, 87), we further investigated Helios as a candidate contributing to the program 
of fetal Treg differentiation.  
 
2.3.6 Fetal naïve T cells have increased Helios protein expression at baseline. 
Using flow cytometry staining, we show that fetal naïve T cells had higher Helios protein 
expression compared to adult naïve T cells (Fig. 11D,E). In comparison, we also examined the 
protein expression of two other Treg-specific genes with increased transcription in fetal naïve T 
cells that had differentially enriched ATAC signal, (CCR4; Fig. 12C) or H3K27ac signal (Eos; 
Fig. 12D). Using FOXP3 expression as a reference, CCR4 and Eos expression did not 
demonstrate a similar shift in expression within fetal naïve T cells from adult naïve T cells when 
compared to Helios expression (Fig. 12E), which led us to focus on investigating Helios 
expression in fetal naïve T cell differentiation. As previously described (63, 88), we identified 
Helios- and Helios+ FOXP3+ populations in adult Treg cells (Fig. 11F). Fetal Treg cells were all 
uniformly Helios+, which could be indicative that retention of permissive epigenetic marks at 
Helios Treg-accessible SEs may drive high Helios expression (Fig. 11F).  An average of 60% of 
fetal naïve T cells were Helios+, while adult naïve T cells did not express Helios (Fig. 11F&G).  
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2.3.7 The predisposition of fetal naïve T cells towards Treg differentiation is not explained by 
recent thymic emigrant (RTE) abundance or increased proliferative ability. 
Previous studies have demonstrated that CD31+ RTEs within the human naïve T cell population 
(89) have increased Treg differentiation potential, making them potential precursors of Treg cells 
in the periphery. We sought to evaluate if increased RTE proportions was a contributor to 
increased Treg differentiation in fetal naïve T cells, since the fraction of CD31+ RTEs are highest 
at birth and decline with age (90). Using flow cytometry, we assessed CD31 staining in sorted 
fetal and adult naïve T cells (sort strategy in Fig. 1), setting the negative gates based on 
memory populations in CD4 T cell controls as well as isotype controls (Fig. 13A). Unexpectedly, 
CD31+ RTE proportions were not different between adult and fetal naïve T cell populations (Fig. 
13B. Because CD31+ RTEs did not demonstrate increased differentiation in the absence of 
exogenous TGFβ (67), we concluded that the predisposition towards Treg differentiation that we 
observed within fetal naïve T cells was not attributed to differences in RTE proportions. We 
further observed that mean CD31 expression levels were reduced within fetal RTEs (Fig. 13C). 
CD31 is downregulated with TCR signaling (90), and a subset of fetal CD4+ T cells are CD69+ 
and actively cycling (39). We therefore assessed the expression of CD69 and Ki-67, a marker of 
active proliferation, in fetal naïve T cells relative to Helios expression. Neither fetal nor adult 
naïve T cells express CD69 (Fig. 14A), regardless of Helios expression. However, as previously 
characterized (39), a small subset of fetal naïve T cells are actively proliferating, while adult 
naïve T cells are mainly Ki-67- (Fig. 14B), thus possibly accounting for the reduced CD31 
expression in fetal naïve T cells. The majority of the Ki-67+ population in fetal naïve T cells was 
also Helios+ (Fig. 14C), suggesting that Helios might regulate proliferation. However, with TCR 
stimulation, both adult and fetal naïve T cells upregulated Ki-67 to a similar extent after 5 days, 
indicating that Helios expression does not confer any selective proliferation advantage on fetal 
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naïve T cells during Treg differentiation that may account for their increased Treg differentiation 
potential.  
 
2.3.8 Fetal naïve T cells do not have increased demethylation at the FOXP3 Treg-specific 
demethylated region (TSDR)  
As Helios was first identified as a marker of thymic Treg cells (63), we sought to rule out possible 
contamination of thymic Treg cells by assessing demethylation of the TSDR at the conserved 
non-coding sequence 2 (CNS2) region within the FOXP3 gene in our sorted naïve T cell 
populations (Fig. 1). We saw that as expected, only fetal and adult Treg populations had 
complete TSDR demethylation, while both fetal and adult naïve T cells had a fully methylated 
TSDR (Fig. 15A). This indicated that Helios expression within fetal naïve T cells was cell-
intrinsic and not due to contamination with thymic Treg cells.   
 
2.3.9 Fetal naïve T cells upregulate and maintain Helios expression during iTreg differentiation  
Helios is expressed independently of FOXP3 expression (28, 56, 67) and can enhance the 
acquisition of a Treg-transcriptional signature with the co-expression of FOXP3 (57). As such, 
Helios expression in fetal naïve T cells, but not in adult naïve T cells, might allow them to 
bypass the need for TGFβ to initiate FOXP3 upregulation and underlie their preferential 
differentiation into Treg cells. To assess this, we tracked Helios expression within fetal and adult 
naïve T cells during Treg differentiation with IL-2 alone or with TGFβ added at 1, 3, or 5 days. As 
previously observed, a higher frequency of fetal naïve T cells differentiated into CD25hiFOXP3hi 
iTreg cells relative to adult naïve T cells either in the presence or absence of exogenous TGFβ 
(40, 41) (Fig. 17A,B). Fetal naïve T cells highly upregulated and maintained Helios protein 
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expression during the process of iTreg differentiation, whereas adult naïve T cells did not (Fig. 
17C,D). Concurrent upregulation of both FOXP3 and Helios was observed only in fetal iTreg cells 
differentiated in both stimulation conditions; even as FOXP3 expression increased with TGFβ 
stimulation, Helios expression was not upregulated in adult iTreg cells at any time point (Fig. 16A, 
B). Although Helios has been implicated as a marker of activation in proliferating cells (91), we 
show that both fetal and adult iTreg cells upregulated Ki-67 expression to the same extent, but 
only fetal iTreg maintained upregulation of Helios (Fig. 17E), thus excluding the probability that 
Helios upregulation in fetal iTreg cells is a result of increased cell proliferation. We also excluded 
the possibility of thymic Treg outgrowth leading to Helios expression within fetal naïve T cells by 
sorting (Fig. 15B) and assessing TSDR demethylation in adult FOXP3- and FOXP3+Helios- iTreg 
populations (Fig. 15C). As previously shown (38, 92, 93), we did not detect any TSDR 
demethylation for adult iTreg cells differentiated in vitro (Fig. 15A). Assessment of sorted fetal 
FOXP3-, FOXP3+Helios- and FOXP3+Helios+ IL-2- or TGFβ-iTreg populations (Fig. 15D,E) did not 
reveal TSDR demethylation in any fetal iTreg populations (Fig. 15A), thus suggesting that the 
increase in Helios expression happens de novo in fetal iTreg cells and not from the outgrowth of 
thymic Treg cells.  
 
The proportions of fetal IL-2-iTreg cells generated across time tracked closely with proportions of 
adult TGFβ-iTreg cells (Fig. 17B), suggesting that Helios expression within fetal naïve T cells 
could enhance their preferential differentiation into Treg cells independently of exogenous TGFβ. 
We further examined fetal Helios+ and Helios- populations after Treg differentiation and found that 
the majority of fetal iTreg cells were within the Helios+ population 24 hours after the initiation of 
Treg induction (Fig. 16C). The increased frequency of iTreg cells present within the Helios+ over 
the Helios- population was maintained over time and in both stimulation conditions (Fig. 16D). 
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The Helios+ population also consistently had higher FOXP3 expression (Fig. 16E) relative to 
Helios- cells, suggesting that Helios expression could potentially drive increased FOXP3 
expression in differentiating fetal naive T cells.  
 
2.3.10 Helios knockout in fetal naïve T cells impairs their ability to preferentially differentiate into 
Treg cells  
Given our hypothesized role of Helios in enhancing FOXP3 upregulation during fetal Treg cell 
differentiation, we predicted that reduced Helios expression in fetal naïve T cells would 
subsequently inhibit their cell-intrinsic propensity for Treg differentiation. Using CRISPR 
(clustered regular interspaced short palindromic repeats)-Cas9 (CRISPR-associated protein 9) 
mediated editing, we knocked out Helios with two independent guide RNAs (gRNAs) targeting 
different exons of the gene. Fetal naïve T cells were then assessed for Treg induction post 
editing after differentiation in the presence or absence of exogenous TGFβ (Fig. 19A). We first 
confirmed that both gRNAs were able to successfully disrupt the Helios locus (Fig. 18A-C), and 
observed specific reduction of Helios protein in fetal naïve T cells (Fig. 19B) in comparison to a 
non-targeting (NT) guide. Both gRNAs resulted in an average of 70% of fetal naïve T cells losing 
Helios expression (Fig. 18D), and the reduction was maintained after 6 days of Treg induction in 
both stimulation conditions (Fig. 19B). Helios knockout in stimulated fetal naïve T cells reduced 
subsequent Treg differentiation in the absence of exogenous TGFβ compared to cells that 
received the NT guide (Fig. 19C,D), and the reduction in Treg percentage correlated with the 
extent of knockout generated (Fig. 20A). Adult naïve T cells nucleofected with the same guides 
were used as Treg gating controls (Fig. 18E). In contrast, Helios knockout had no effect on fetal 
iTreg differentiation with addition of exogenous TGFβ (Fig. 19C,D, Fig. 20B). This indicated that 
signaling via TGFβ compensated for the loss of Helios-driven Treg differentiation, and that Helios 
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and TGFβ may participate in shared signaling pathways. Our data show that Helios expression 
within fetal naive T cells plays a role in enhancing preferential Treg differentiation specifically in 
the absence of exogenous TGFβ. This mechanism present within fetal naïve T cells could lower 
the threshold required for Treg cell differentiation, thus potentially allowing for the default 
generation of peripheral Treg-mediated tolerance upon antigen encounter during fetal 
development.  
 
2.3.11 Helios suppresses IL-2 secretion in fetal iTreg cells. 
Helios maintains an anergic and non-proliferative state characteristic of the Treg phenotype (94) 
by mediating the epigenetic silencing of the IL2 locus in Treg cells (95). In contrast to 
conventional T cells, Treg cells have reduced IL-2 production upon TCR stimulation and depend 
heavily on paracrine IL-2 for their maintenance (96). Since Helios is highly expressed and 
maintained in only fetal iTreg, we investigated whether this led to a corresponding suppression of 
IL-2 secretion. As hypothesized, fetal iTreg cells demonstrated less IL-2 production upon 
restimulation compared to adult iTreg cells (Fig. 21A), and suppression of IL-2 production was 
observed regardless of iTreg differentiation conditions (Fig. 21B). When delineated on the basis 
of Helioshi and Helioslo expression (Fig. 21C), Helioshi fetal iTreg cells consistently had lower IL-2 
production across both stimulation conditions (Fig. 21D), suggesting that high Helios expression 
may be associated with greater repression of the IL2 locus. Helios knockout in fetal iTreg cells 
then resulted in increased IL-2 production in IL-2-iTreg cells (Fig. 21E,F). Furthermore, even 
though the addition of exogenous TGFβ compensated for loss of Helios during Treg 
differentiation, Helios knockout TGFβ-iTreg cells produced more IL-2 upon restimulation when 
compared to the NT control (Fig. 21E,F). This demonstrates that continued Helios expression in 
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fetal naïve T cells not only enhances preferential Treg differentiation, but also represses IL-2 
production in fetal iTreg cells.  
 
2.3.12 Helios knockout results in the downregulation of genes associated with Treg differentiation 
and function and the concurrent upregulation of pro-inflammatory genes 
Helios also controls the expression of several key genes involved Treg suppressive function (97) 
including LRRC32 (GARP). Helios knockout in fetal naïve T cells did not impact FOXP3 or 
CD25 expression (Fig. 20C, D), but resulted in decreased CTLA-4 expression in fetal iTreg cells 
(Fig. 20E). Helios knockout also resulted in a trend towards downregulation of GARP and LAP 
on fetal iTreg cells (Fig. 20F), reaching significance in fetal IL-2-iTreg cells (Fig. 20G). Since the 
impact of Helios knockout was variable across the Treg markers surveyed, and only fetal iTreg 
cells retain expression of a partial Treg-specific transcriptional signature, we further assessed the 
impact of Helios ablation on the fetal iTreg transcriptome by RNA sequencing. CRISPR-Cas9 
editing was carried out in fetal naïve T cells with Helios gRNA1 (HeliosKO) or the non-targeting 
control guide (HeliosWT) before Treg differentiation was induced in the absence or presence of 
TGFβ (Fig. 22A).  
 
PCA revealed that HeliosKO and HeliosWT iTreg cells segregated largely according to whether 
differentiation occurred in the presence or absence of TGFβ (PC1, Fig. 22B). This was not 
unexpected, since TGFβ signaling is responsible for the upregulation and repression of a 
significant subset of Treg-specific genes (Fig. 4B-D). We also detected a small but distinct 
segregation of HeliosKO from HeliosWT cells, with PC2 mainly segregating HeliosKO  and HeliosWT 
IL-2-iTreg cells (Fig. 22C), while PC3 mainly distinguished HeliosKO and HeliosWT TGFβ-iTreg cells 
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(Fig. 22D). As full knockout of Helios expression is not achieved within the total iTreg population 
with an average of 30% of all cells still retaining Helios expression (Fig. 22A), we expected that 
this would result in a lowered signal-to-noise ratio. We thus utilized a more generous cutoff, 
where genes with at least a 10% change in expression (FC>1.1, FDR<0.05) were defined to be 
differentially expressed (Fig. 22E,F).  
 
Given that TGFβ signaling is able to compensate for the defect in Treg induction in HeliosKO iTreg 
cells (Fig. 19D,E), we decided to evaluate potential pathways by which Helios might play parallel 
or additive roles relative to TGFβ signaling. We first looked for genes upregulated (FDR<0.05, 
FC>1.1) with TGFβ signaling within HeliosWT iTreg cells that were subsequently downregulated 
in HeliosKO cells within both stimulation conditions. Genes with expression enhanced by Helios 
in parallel would be downregulated in HeliosKO IL-2-iTreg cells, but due to compensation with 
TGFβ signaling, would show no change in expression in HeliosKO TGFβ-iTreg cells. In contrast, 
genes with expression enhanced by Helios and TGFβ in an additive manner would have 
decreased expression in HeliosKO TGFβ-iTreg cells. Similar cutoffs were used to define 
upregulated genes in HeliosKO iTreg cells. We identified 199 downregulated and 161 upregulated 
genes within HeliosKO IL-2-iTreg cells that were not differentially expressed in TGFβ-iTreg cells 
(Fig. 23A, left). HeliosKO IL-2-iTreg cells had reduced expression of Treg-specific genes previously 
identified to be exclusively upregulated in fetal iTreg cells such as DUSP4, IL10 and ITGAE 
(CD103) (Fig. 23A, left, Table 10). Concurrently, HeliosKO IL-2-iTreg cells upregulated several 
chemokine and tumor necrosis factor (TNF) superfamily genes (Fig. 23A, left), indicating that 
Helios may enhance the expression of a subset of Treg genes while simultaneously reducing 
expression of pro-inflammatory genes associated with effector function in the absence of TGFβ 
signaling.  
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We next found that Helios expression contributed to the upregulation of an additional 351 genes 
in TGFβ-iTreg cells (Fig. 23A, right), including SEMA4, PTGS1 and RTKN, previously identified in 
the TGFβ induced Treg gene signature (Cluster 2.2, Fig. 4B, Table 10), as well as TOX2 and 
RGS1, which are upregulated in fetal but not adult iTreg cells (Cluster 2.3, Fig. 4B, Table 10). 
Additionally, HeliosKO TGFβ-iTreg cells had upregulation of 251 genes relative to HeliosWT; genes 
upregulated included chemokine receptor genes, as well as transcription factors involved with 
Th1, Th2 and Th17 cell differentiation and function such as PRDM1 (Blimp1)(98), GATA3 (99), 
IKZF1 (Ikaros) (100, 101), and MAF (c-MAF) (102)(Fig. 23A, right). These data suggest that 
Helios performs both parallel and additive roles in enhancing the upregulation of genes 
associated with the Treg transcriptional signature and repressing genes that might drive 
differentiation towards other effector T cell pathways during Treg differentiation. 
 
Lastly, we identified genes that were either upregulated or downregulated in HeliosKO iTreg cells 
across both induction conditions, implicating possible transcriptional control by Helios 
independent of TGFβ signaling during differentiation. 200 genes were downregulated in HeliosKO 
iTreg cells generated in both stimulation conditions, including genes related to Treg phenotype and 
function such as CTLA4 and LTBP4 (Fig. 23B). Although we did not observe reduced protein 
expression of FOXP3 in HeliosKO iTreg cells at Day 6 (Fig. 20C), we observed decreased FOXP3 
transcription across both iTreg populations, suggesting that additional post-transcriptional 
mechanisms probably regulate FOXP3 expression downstream of Helios. Additionally, HeliosKO 
iTreg cells across both conditions have reduced expression of the NFATC4 (NFAT3) and PPARA 
(PPARα) transcription factors which regulate the repression of pro-inflammatory cytokines such 
as IL-2, IFNγ and TNFα (103, 104), as well as the histone H3K27 demethylase KDM6B 
(JMJD3), which suppresses Th2 and Th17 programs (105) (Fig. 23B). Loss of Helios expression 
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also led to the upregulation of 88 genes, including genes attributed to pro-inflammatory effector 
T cell function such as IFNG (Fig. 23B). Taken together, we show that Helios plays a role in 
enhancing fetal Treg differentiation through the transcriptional regulation of a key subset of genes 
that restrict differentiation towards effector T cell helper phenotypes while favoring differentiation 
towards the Treg cell fate.  
 
2.3.13 Helios knockout fetal iTreg cells have decreased IL-10 and increased IFNγ production 
The regulation of cytokine production in Treg cells is important for their suppressive ability; Treg 
cells must repress secretion of pro-inflammatory cytokines such as IFNγ while maintaining 
production of immunosuppressive cytokines such as IL-10 (33). The loss of Helios expression in 
committed Treg populations in mice result in subsequent IFNγ production (64, 65), and we show 
that fetal HeliosKO iTreg cells have increased IFNγ transcription relative to HeliosWT iTreg cells 
(Fig. 23B). Furthermore, fetal, but not adult, iTreg populations have increased IL10 transcription 
(Fig. 4B). We next assessed IL-10 and IFNγ concentrations in culture supernatant during iTreg 
differentiation. We first confirmed that only fetal, but not adult, iTreg cells, produced IL-10 during 
iTreg differentiation in the absence of TGFβ, and this is further augmented by exogenous TGFβ 
(Fig. 24A), which may be related to an increased frequency in Treg cell differentiation (Fig. 7B). 
Fetal iTreg cells also produced less IFNγ than adult iTreg generated in both stimulation conditions 
(Fig. 24B). Lastly, fetal IL-2-iTreg cells had a greater ratio of IL-10 produced over IFNγ compared 
to their adult counterparts, and this effect was greatly enhanced in TGFβ-iTreg cells (Figure 24C). 
Ablation of Helios in fetal iTreg cells then resulted in a reduction of IL-10 produced in HeliosKO IL-
2-iTreg cells with both gRNA1 and 2 (Fig. 24D). We observed a small but sustained decrease in 
IL-10 across all HeliosKO TGFβ-iTreg cells that received gRNA1 but did not detect this decrease 
in gRNA2 (Fig. 24D), which reflected our RNA sequencing results showing a minimal decrease 
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in IL-10 in HeliosKO TGFβ-iTreg that did not meet fold change cutoffs (Fig. 22G). This consistent 
with our prediction from our RNAseq sequencing results that TGFβ signaling can compensate 
Helios knockout to upregulate IL10 transcription within HeliosKO TGFβ-iTreg (Figure 23A). Helios 
knockout within fetal iTreg cells resulted in increased IFNγ production in HeliosKO TGFβ-iTreg 
cells, but the effect was less obvious in IL-2-iTreg cells (Fig. 24E). However, across all 
differentiation conditions and both gRNA, HeliosKO iTreg cells had a striking decrease in their IL-
10 to IFNγ ratio (Fig. 24F), especially in HeliosKO fetal TGFβ-iTreg, where the majority of samples 
tipped from a pro-tolerance (ratio>1) to pro-inflammatory cytokine (ratio<1) profile. Overall, this 
suggests an important role for Helios in regulating the cytokine output of fetal iTreg cells, which 
could help prevent pro-inflammatory responses which can be detrimental in utero.  
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2.4 DISCUSSION 
The predisposition of human fetal naïve T cells towards Treg cell differentiation presents a 
opportunity to identify potential underlying cell-intrinsic factors that can be utilized to improve in 
vitro iTreg cell generation for cell-based immunotherapies. We show here that fetal naïve T cells 
already have the partial expression of a Treg-specific transcriptome and epigenome, and that 
only fetal-derived iTreg cells retain expression of this transcriptome upon differentiation in vitro. 
Furthermore, we observed that fetal naïve T cells had increased chromatin accessibility at 
approximately a third of all defined Treg-accessible enhancers, but only a small percentage of 
these were marked by H3K27ac. This suggests that many Treg-specific enhancers are held in a 
poised (i.e., accessible), but not active state in quiescent fetal naïve T cells. As such, the full 
acquisition of the Treg-specific epigenetic, and subsequently, transcriptional signature might only 
occur upon TCR activation and/or cytokine signaling which triggers the final commitment to the 
Treg cell fate. Furthermore, we discover two active SEs associated with Helios that also showed 
increased transcription and protein expression in fetal naïve T cells. These data thus implicate a 
broad landscape of Treg-poised chromatin in fetal naïve T cells that contribute to their propensity 
for Treg differentiation, and identified Helios as an important transcription factor whose 
expression distinguishes fetal and adult naïve T cells. However, it is plausible that there is also 
a contribution of additional histone marks to the overall chromatin landscape in addition to the 
two permissive epigenetic characteristics we profiled. For example, since Helios has been 
shown to interact with other histone modifying proteins such as the NuRD co-repressor complex 
(106, 107), sequencing of additional histone marks such as the repressive H3K27me3 mark 
would allow us to assess possible repression of genes associated with other effector lineages. 
Additionally, future experiments that identify Helios binding sites by Helios ChIPseq within fetal 
naïve or iTreg populations would be critical to determine if Helios is a driving factor behind the 
acquisition of active or suppressive epigenetic marks at key Treg-specific genes. These further 
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analyses would reveal a more complete picture of the fetal epigenome and how it contributes to 
the overall Treg cell differentiation phenotype.  
 
Our group and others have shown that the human fetal immune system is skewed towards 
tolerance by the presence of a large Treg cell population (40, 41) which is likely derived from 
preferential conversion of fetal naive T cells into Treg cells upon antigen encounter (42). Here, we 
show that Helios enhances the preferential differentiation and phenotypic commitment of fetal 
naïve T cells towards the Treg cell fate. Ablation of Helios expression in fetal naïve T cells 
specifically impaired their cell-intrinsic predisposition for iTreg differentiation, and reduction in Treg 
proportions were correlated with the extent of Helios knockout. Although the addition of 
exogenous TGFβ compensates for loss of Helios during Treg generation, Helios knockout still 
resulted in the subsequent downregulation of Treg-specific genes and upregulation of pro-
inflammatory genes involved in effector T cell differentiation and function in fetal iTreg cells. This 
is consistent with the known role of Helios in restraining effector Th1 and Th17 cell programs 
within committed Treg cells in mice (64, 65). Our results suggest that transcriptional regulation by 
Helios may play a dual role in fetal Treg differentiation – first, by enhancing Treg differentiation 
through upregulation of a set of Treg-specific genes even in the absence of TGFβ, and second, 
by repressing pro-inflammatory genes and genes that mediate differentiation towards other 
effector T cell subsets. This fine-tuning of the fetal iTreg transcriptome subsequently impacts Treg 
function, as the loss of Helios uniformly results in the upregulation of IFNγ over IL-10 in both 
fetal IL-2- and TGFβ- iTreg cells. Helios deficiency in mouse Treg cells in vivo does not result in 
overt distortions in FOXP3 expression or Treg proportions at steady state (108), but rather in the 
loss of immunosuppressive ability and the manifestation of autoimmunity in later life or in 
response to inflammatory insults (64, 65). Regulation of cytokine and other pro-inflammatory 
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genes by Helios could then potentially play a role in maintaining the phenotypic stability of fetal 
iTreg cells in utero to prevent unwanted pro-inflammatory responses. 
 
Given the nature of this study, and the exclusive use of primary human cells, there are important 
limitations to acknowledge in its interpretation. We primarily compared T cells isolated from fetal 
spleen and adult peripheral blood for our studies, due to the difficulty of obtaining adult splenic 
tissue and fetal peripheral blood. While we cannot fully rule out immunological differences 
associated with ontogeny and environmental polarization, we have attempted to reduce 
confounders resulting from this factor by only deriving the epigenetic Treg signature by 
comparing adult naïve and adult Treg cell populations, to ensure that only the Treg signature was 
the main point of comparison between adult and fetal populations. We were able to additionally 
rule out contributions from age specific differences by selecting genes shared between adult 
and fetal Treg cells in our RNAseq experiments to ensure that only genes truly contributing to the 
Treg cell phenotype were included. Gestational age, and on some occasions when it could be 
determined, sex, were the only demographics collected for our fetal samples. Hence, we were 
unable to fully rule out any other potential confounders or stratify our samples accordingly. 
Furthermore, technical variation due to the kinetics of CRISPR-Cas9 editing, together with the 
inherent biological variability in primary human samples manifested in the high donor variability 
that we observed within our editing experiments. Lastly, we also observed heterogeneity in 
Helios expression at steady state in fetal naïve T cells, as well as the extent of Helios 
upregulation from sample to sample, which could contribute to differences in Treg differentiation. 
We envision that future work will aim to utilize single cell sequencing techniques to separate and 
identify populations that will explain the observed biological heterogeneity, and possibly identify 
subsets that have greater predisposition towards Treg differentiation.  
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Our work here suggests a key role for Helios in establishing early life peripheral tolerance in 
humans, and there are some indications to support this hypothesis from studies in neonatal 
mice. Notably, when Helios-/- mice were first generated, the authors reported the presence of 
significant fatality in the first two weeks of neonatal life, and a 100% fatality was observed with 
subsequent crosses to achieve a full B6 background (108). This timing coincides with the 
emergence and migration of functional T cells into the secondary lymphoid organs within the 
neonatal mouse, and is developmentally equivalent to when T cells emerge in the second 
trimester in humans (51). Furthermore in mice, thymic Treg cell populations generated in an early 
window from birth to 10 days later have been shown to be qualitatively different from those 
generated later in life (109), indicating that Treg cell populations generated in early life are 
indispensable to the maintenance of lifelong tolerance. However, these studies did not examine 
the potential contributions of peripheral Treg differentiation from naïve T cells, which may account 
for a large percentage of the tolerogenic phenotype observed in the human fetus. This is 
particularly significant since there is an increased frequency of rapidly proliferating CD4+ and 
CD8+CD25- human fetal T cell populations (39) that could potentially bear auto-reactive TCRs 
that have escaped thymic deletion as observed in neonatal mice (110). In light of our data 
presented here, we thus speculate that Helios plays a previously unappreciated role in the 
generation of peripheral Treg cells in this critical period in early human fetal development where 
the need for peripheral tolerance is perhaps the most acute.  
 
In vitro human Treg cell differentiation from naïve T cells for therapeutic purposes has 
encountered significant roadblocks due to difficulties in obtaining pure populations of Treg cells 
that maintain a stable phenotype over time (38, 92, 93). Although Helios+ fetal iTreg cells did not 
show demethylation at the FOXP3 TSDR, Helios+, but not Helios- ex vivo Treg cells retain a more 
highly demethylated TSDR when expanded in vitro (111, 112). It is thus highly likely that this 
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reflects the inability of in vitro differentiation to capture the conditions or environmental factors 
that trigger TSDR demethylation. Regardless, we show that fetal, but not adult iTreg cells are 
phenotypically more similar to ex vivo Treg cells, since they retain expression of Helios, 
demonstrate suppression of IL-2 production upon restimulation, and produce IL-10 in with Treg 
differentiation. These attributes are commonly associated with the Treg cell phenotype, but are 
not acquired in adult human iTreg cell populations. Lastly, given that our data shows that Helios 
enhances the expression of genes that favor Treg over helper T effector commitment, this may 
represent a mechanism by which Helios maintains stable Treg function and identity in vivo (64, 
65, 88, 95, 97). Future studies are thus required to assess this possibility, particularly in pro-
inflammatory environments, and whether manipulation of Helios expression within adult naïve T 
cells can recapture this effect. Additionally, given the importance of the Treg-specific epigenome 
to function and stability (28, 30), further identification of upstream factors that drive the 
acquisition of the permissive enhancer landscape in fetal naïve T cells will likely provide 
important insights for generating stable iTreg cells from adult naïve T cells. This work will be 
relevant for improving strategies to generate iTreg cells for use in for immunotherapy to establish 
tolerance in autoimmunity and transplantation. 
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Figure 1. Gating strategy and purity assessment for sorted naïve and Treg cells. 
(A) Gating strategy for FACS sorting of CD4+ naïve and Treg cells based on adult peripheral 
mononuclear cells after magnetic pre-enrichment for CD4+ T cells.  
(B) Flow cytometry analysis post-sorting to assess sort purity for CD27+CD45RA+ fetal and adult 
naïve T cells. Percentages indicate proportion of naïve T cells gated in (A).  
(C) Flow cytometry analysis post-sorting to verify the lack of CD25hiFOXP3+ Treg cells present in 
sorted naïve fetal and adult T cell populations.  
(D) Flow cytometry analysis post-sorting to assess sort purity for CD25hiCD127lo adult and fetal 
Treg cells (left) gated in (A), and to confirm expression of FOXP3 (right). 
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Figure 2. Definition of the Treg transcriptional signature 
The Treg transcriptional signature is defined from genes with increased/decreased transcription 
in adult and fetal Treg populations relative to adult naïve T cells. Cut-offs were set at false 
discovery rate <0.05 (FDR), and log2 fold change>1.5 (log2FC). Scatterplot plots log2FC values 
for comparisons of adult naïve against adult Treg (y axis) and adult naïve against fetal Treg (x 
axis). Dotted lines in grey denote log2FC cut-offs. Treg upregulated (orange) and downregulated 
genes (blue) are shown. Genes previously associated with Treg and naïve T cell function are 
labeled.  
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Figure 3.  Fetal naïve T cells have expression of a partial Treg transcriptome 
(A) Cells segregate first by cell origin (Principal Component, PC1, adult versus fetal), then by 
functional subtype (PC2, naïve versus Treg). Boxplots show scores for PC1 and 2 (bottom and 
right respectively). 
(B) Fetal naïve T cells have a partial Treg transcriptional signature. Heatmap shows relative 
expression levels of Treg-specific differentially expressed (DE) genes in adult naïve (AN), fetal 
naïve (FN), adult Treg (AT) and fetal Treg (FT). Clusters are labeled and defined by k-means 
clustering. Genes associated with Treg and naïve T cell function are labeled. Boxplots (left) show 
the averaged trimmed mean of M values (TMM) normalized reads across all upregulated (top, 
Cluster 1&2) and downregulated (bottom, Cluster 3&4) genes. Kruskal-Wallis test and Dunn’s 
multiple comparison test with Bonferroni correction for multiple testing, *** p<0.001, n.s., p>0.05 
(n = 4 biological replicates per group).  
 (C) 88 and 42 Treg-specific genes are upregulated (orange) and downregulated (blue) in fetal 
naïve T cells. Volcano plot of DE (log2 fold change >1.5, p.adj<0.05) genes in fetal and adult 
naïve T cells, all DE genes in light grey. Dotted lines (grey) denote fold change cut-offs. Among 
Treg-upregulated genes, genes previously associated with Treg function are labeled. Among Treg-
downregulated genes, the top five genes with the lowest p.adj values are labeled.   
All boxplots in this figure show median (centre line), interquartile range (box) and tenth and 
ninetieth percentiles (whiskers).  
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Figure 4. Fetal induced Treg cells retain expression of the partial Treg-specific 
transcriptome detected in fetal naïve T cells in steady state. 
(A) Fetal and adult iTreg cells segregate first by cell origin (Principal Component, PC1, adult 
versus fetal), then by stimulation received during differentiation (PC2, IL-2 versus IL-2 and 
TGFβ). Boxplots show scores for PC1 and 2 (bottom and right respectively).  
(B) Fetal, but not adult, iTreg cells upregulate a subset of Treg-associated genes independently of 
exogenous TGFβ. Heatmap shows relative expression levels of differentially expressed genes 
(log2 fold change >1.5, false discovery rate, FDR<0.05) in adult and fetal iTreg differentiated with 
IL-2 (IL-2-iTreg) or IL-2 and TGFβ (TGFβ-iTreg). Clusters are labeled and defined by k-means 
clustering. Genes associated with Treg or pro-inflammatory/effector T cell function are labeled.  
(C) Fetal iTreg populations have enrichment of genes upregulated in ex vivo activated Treg cells. 
Pre-ranked Gene Set Enrichment Analysis (GSEA) was used to assess overrepresentation of 
pre-defined activated Treg-associated gene sets (see figure S3B for details of all gene sets) in 
fetal (orange) or adult iTreg cells (blue) differentiated with IL-2 (left) or IL-2 and TGFβ (right), n=4 
for all conditions. Barplot shows normalized Enrichment Scores (ES) for gene sets with 
FDR<0.05, arrows denote direction of enrichment in adult or fetal iTreg cells. 
(D) Fetal iTreg populations have differential expression of the partial Treg-specific signature  
detected in primary fetal naïve T cells. Pre-ranked GSEA was used to assess 
overrepresentation of each of the gene clusters identified in Figure 1B. Barplot shows 
normalized Enrichment Scores (ES) for all clusters with FDR <0.05 for fetal (orange) or adult 
(blue) iTreg cells differentiated with IL-2 (left) or IL-2 and TGFβ (right). 
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Figure 5. Assessing the enrichment of Treg upregulated or downregulated genes in fetal 
and adult induced Treg (iTreg) populations  
(A) Boxplots show averaged log2(n+1) trimmed mean of M values (TMM) normalized reads 
across each cluster identified in Figure 2D. Statistics were calculated with Kruskal-Wallis test 
and Dunn’s multiple comparison test with Bonferroni correction for multiple testing, *** p<0.001 
(n = 4 biological replicates per group).  
(B) Pre-defined gene sets used for Gene Set Enrichment Analysis (GSEA). See Supplementary 
Methods and Materials for details on gene set definition.  
(C) Fetal iTreg cells differentiated in IL-2 alone (IL-2-iTreg) have increased enrichment of genes 
previously defined to be upregulated in ex vivo fetal naïve, adult, and fetal Treg cells. Lineplot 
shows the running enrichment score (ES) as the analysis goes through the pre-ranked gene list 
comparing fetal against adult IL-2-iTreg cells. Genes from Cluster 1.2 appearing within the pre-
ranked list are highlighted below the lineplot.  
(D) Fetal iTreg cells differentiated in IL-2 and TGFβ (TGFβ-iTreg) additionally have enrichment of 
genes previously defined to be upregulated only in ex vivo adult and fetal Treg cells. Lineplots 
show running ES through the pre-ranked gene list comparing fetal against adult TGFβ-iTreg cells 
for Cluster 1.2 (left) and Cluster 1.1 (right) genes. Genes from each cluster appearing within the 
pre-ranked list are highlighted below the respective lineplots.  
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Figure 6. Fetal induced Treg cells have increased sensitivity to TGFβ signaling.  
(A) Fetal induced Treg (iTreg) cells have increased expression of genes involved in downstream 
TGFβ signaling. Boxplots show log2 trimmed mean of M values of normalized RNAseq reads for 
LRRC32, LIN28B, TGFBR3 and SMAD1 in fetal (orange) or adult (blue) iTreg differentiated in 
IL-2 alone (IL-2-iTreg) or with exogenous TGFβ added (TGFβ-iTreg), n=4 for all conditions.  
(B) Fetal, but not adult, iTreg cells have increased GARP(LRRC32) expression. Boxplots show 
mean fluorescence intensity (MFI) of GARP by flow cytometry staining in adult and fetal IL-2-
iTreg cells (n=15, 28 respectively) and TGFβ-iTreg cells (n=14, 28 respectively).  
(C) Fetal, and not adult iTreg cells highly upregulate GARP and latency associated peptide 
(LAP). Representative flow cytometry plots (left) are shown for one experiment gated on live, 
CD4+CD25hiFOXP3hi iTreg cells. Boxplots show quantification of GARP+LAP+ adult and fetal IL-2-
iTreg (n=7,11 respectively) and TGFβ-iTreg cells (n=7,10 respectively).  
 (D) Fetal naïve T cells still retain an increased ability for Treg cell differentiation over adult naïve 
T cells with TGFβ neutralization. Representative flow cytometry plots show one experiment for 
live, CD4+ cells.  
(E) Quantification of percentages of CD25hiFOXP3hi iTreg cells as shown in (D). Sorted adult and 
fetal naïve T cells were stimulated with αCD3/αCD28/αCD2 tetramers either in the presence of 
IL-2 only (n=8, 12 respectively), IL-2 with 0.25μg/mL (n=8, 12) or 0.5μg/mL αTGFβ blocking 
antibody (n = 8, 11), or IL-2 with TGFβ (n = 8, 11). All statistics were calculated by unpaired two-
sided Mann-Whitney test, ***p<0.001, **p<0.01, n.s. p>0.05. Boxplots show median (center 
line), interquartile range (box) and tenth and ninetieth percentiles (whiskers). 
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Figure 7. Identification of Treg-accessible and inaccessible enhancers. 
(A,B) Definition of the Treg -accessible/inaccessible enhancer signature. Scatterplots show 
DESeq2 normalized (A) ATAC reads and (B) H3K27ac reads at all stitched superenhancers 
(SEs) and transcriptional enhancers (TEs) for adult Treg cells (x-axis) plotted against adult naïve 
T cells (y-axis). Differentially enriched SEs (dark orange) and TEs (light orange) in Treg cells and 
naïve T cells (dark blue and light blue respectively) are colored. Enhancers proximal to genes 
previously associated with Treg and naïve T cell function are labeled. 
(C) Shared Treg-accessible enhancers are defined as enhancers with both increased ATAC and 
H3K27ac signal in adult Treg cells relative to adult naïve T cells with fold change > 1.5 and false 
discovery rate (FDR) < 0.05 (see Supplementary Methods and Materials for further details). 
Tracks show an example of a Treg-accessible SE at the FOXP3 locus (right), and a common SE 
at the BCL11B locus (left). This was also utilized to define Treg-inaccessible enhancers with 
decreased ATAC and H3K27ac reads. 
(D) Fetal naïve T cells have increased chromatin accessibility relative to adult naïve T cells at 
Treg-accessible enhancers and vice versa. Pie charts show percentage of Treg-accessible 
enhancers with increased chromatin accessibility (left) or Treg-inaccessible enhancers with 
decreased chromatin accessibility (right) in fetal naïve T cells.  
(E) Fetal naïve T cells do not have H3K27ac enrichment relative to adult naïve T cells at Treg-
accessible enhancers and vice versa. Pie charts show percentages and averaged H3K27ac 
normalized log2(n+1) reads across enhancers as with (D).  
(F,G) Boxplots show averaged ATAC (F) and H3K27ac (G) normalized log2(n+1) transformed 
reads across Treg-accessible enhancers (left) and Treg-inaccessible enhancers (right).   Boxplots 
show median (center line), interquartile range (box) and tenth and ninetieth percentiles 
(whiskers). All statistics were calculated using the Kruskal-Wallis test followed by Dunn’s 
multiple comparison test with Bonferroni correction for multiple testing. ***p<0.001, n.s. p>0.05. 
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Figure 8. Fetal naïve T cells have increased ATAC and H3K27ac enrichment at two Treg-
accessible superenhancers associated with Helios 
(A,B) A subset of enhancers is shared between adult Treg and fetal naïve T cells. Principal 
component analysis performed on all super- (SE) and transcriptional enhancers (TE) with 
mapped (A) ATAC or (B) H3K27ac reads. Cells segregate first by age and functional subtype 
(Principal Component, PC1). Fetal naïve T cells (FN) and adult Treg cells (AT) then cluster 
together away from adult naïve T cells (AN) on PC2. Boxplots show scores for PC1 and PC2 
(bottom and right respectively).  
 (C) Fetal naïve T cells have increased/decreased enrichment of epigenetic marks at a subset of 
Treg accessible/inaccessible enhancers. Barplots show number of Treg-accessible/inaccessible 
enhancers with increased (orange) or decreased (blue) ATAC/H3K27ac signal in fetal naïve T 
cells relative to adult naïve T cells (Treg-accessible/inaccessible enhancers defined in 
Supplementary Methods and Materials).  
(D) Key Treg genes are associated with superenhancers in adult Treg cells. Cumulative H3K27ac 
signal at stitched enhancers within 12.5kb are plotted against enhancer rank, and SEs defined 
where the tangent of the plotted curve is 1. Dotted lines (grey) show cutoff for SEs for one 
representative sample each for adult Treg (n = 3). SEs defined as Treg-accessible and meet fold 
change (FC) > 1.5 and false discovery rate (FDR) <0.05 cut-offs are colored in red, and SEs 
associated with key Treg genes are labeled.  
(E) Fetal naïve T cells have a Treg-accessible SE associated with Helios. Plots as with (D) show 
one representative sample for fetal (left) and adult (right) naïve T cells (n = 3). Treg-accessible 
SEs identified in (D) was assessed for differential enrichment in fetal naïve against adult naïve T 
cells and vice versa. Differentially enriched Treg-SEs in each sample with FC>1.5 and FDR<0.05 
are colored red and labeled. TEs associated with key Treg genes in (D) are also labeled. (F,G) 
Fetal naïve T cells have increased ATAC and H3K27ac enrichment at two Treg-accessible SEs 
associated with Helios. Scatterplots of normalized (F) ATACseq reads and (G) H3K27ac reads 
at all stitched enhancer regions of fetal naïve T against adult naïve T cells.  Differentially 
enriched SEs and TEs with FC>1.5 and FDR<0.05 are shown in light grey, with Treg-accessible 
SEs (orange) and Treg-inaccessible SEs (blue). Treg-accessible SEs associated with transcription 
factors labeled; Helios (IKZF2) labeled in bold. 
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Figure 9. Binding motifs for downstream effectors of Treg differentiation are enriched 
within shared Treg-accessible peaks in fetal naïve T cells.  
(A) Fetal naive T cells have increased chromatin accessibility at a third of all defined Treg-
accessible peaks. Pie charts depict percentages of Treg-accessible peaks (See Supplementary 
Methods and Materials for definition of Treg-accessible peaks) that similarly have increased 
chromatin accessibility (left) or H3K27ac enrichment (right) in fetal naïve T cells relative to adult 
naïve T cells.  
(B) The top de novo enriched motif is bound by BATF and the AP-1 complex. DNA motif 
analysis of shared Treg-accessible peaks between fetal naïve and adult Treg cells, with alignment 
of BATF, AP1, FOSL2 and JUNB motifs against the top de novo motif enriched. Other binding 
motifs enriched include (C) RUNX1 and FOXH1, (D) STAT5 and (E) SMAD3 and SMAD2.  
(F) Only a small fraction of Treg-accessible peaks shared between fetal naïve and adult Treg cells 
intersect with FOXP3 binding sites. Bar plots show number of Treg-accessible peaks with 
increased chromatin accessibility and H3K27ac enrichment in fetal naïve T cells, number of 
intersecting FOXP3-bound peaks in red and annotated (see Methods for definition of FOXP3-
bound peaks).  
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Figure 10. The highest ranked super-enhancers shared across all cell populations are 
associated with T cell development and function.  
(A) Shared super-enhancers (SEs) across all cell populations are associated with genes 
involved in T cell development. Shared SEs across adult Treg (top), fetal naïve (center) and adult 
naïve (bottom) T cells within the top 25 SEs for each population are colored in dark grey and 
labelled. Dashed lines (light grey) mark the SE cut-offs.  
(B) Fetal naïve T cells do not have enrichment over adult naïve T cells at Treg-accessible SEs. 
Boxplots show averaged ATAC signals (top) and H3K27ac signals (bottom) across 121 Treg-
accessible SEs in adult naïve (AN), fetal naïve (FN) and adult Treg cells (AT). 
Boxplots show median (centre line), interquartile range (box) and tenth and ninetieth percentiles 
(whiskers). All statistics were calculated using the Kruskal-Wallis test followed by Dunn’s 
multiple comparison test with Bonferroni correction for multiple testing. ***p<0.001, n.s. p>0.05. 
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Figure 11. Helios expression is increased in fetal naïve T cells. 
(A) H3K27ac and ATAC signals at two Treg accessible super-enhancers (SEs) associated with 
the Helios (IKZF2) locus are differentially enriched in fetal naïve T cells relative to adult naïve T 
cells. Representative tracks of one replicate shown (H3K27ac ChIPseq, n=3, ATACseq, n=2).  
(B) Helios is the top gene contributing to the negative directionality of principal component 2 
(PC2). The top 5 genes contributing to PC2, which segregates cells by functional subtype (naïve 
versus Treg) are plotted for both directions; Helios (IKZF2) highlighted in red.  
(C) Transcription of Helios is increased in fetal naïve T cells. Boxplot shows log2 trimmed mean 
of M values of normalized RNAseq reads for Helios in adult naïve (AN), fetal naïve (FN), adult 
Treg (AT) and fetal Treg (FT) cells (n=4).  
(D) Helios protein expression is increased in fetal naïve T cells. Helios staining intensity in 
sorted CD4+CD25-CD27+CD45RA+ adult (blue) and fetal naïve (green), and adult 
CD25hiCD127loFOXP3 (orange) and fetal Treg (brown).  
(E) Boxplot shows quantification of mean fluorescence intensity of Helios for adult naïve (AN, 
n=8), fetal naïve (FN, n=10), adult Treg (AT, n=8), and fetal Treg (FT, n=10) cells.  
(F) Flow cytometry analyses of sorted populations in (D) show that a large proportion of fetal 
naïve T cells are Helios+. Helios+ and Helios- gates were set based on negative and positive 
populations in adult Treg samples (bottom left). Adult naïve T cells were universally Helios-. 
(G) Quantification of Helios+ cells among sorted populations in (F).  
All statistics were calculated by unpaired two-sided Mann-Whitney test. ***p<0.001, **p<0.01, 
*p<0.05. All boxplots show median (centre line), interquartile range (box) and tenth and ninetieth 
percentiles (whiskers) 
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Figure 12. Chromatin accessibility and H3K27ac enrichment at the Helios locus in fetal 
naïve T cells correlate with increased RNA and protein expression. 
(A) Normalized H3K27ac (left, n=3) and ATAC read counts (right, n=2 with 2 technical 
replicates) at the intragenic Treg-accessible SE at the Helios locus for adult naïve (AN), fetal 
naïve (FN) and adult Treg samples.  
(B) Normalized H3K27ac (left) and ATAC read counts (right) at the upstream Treg-accessible SE 
at the Helios locus for AN, FN and AT.  
(C) Intersect of Treg-specific genes associated with: (1) increased ATAC signal at Treg-accessible 
enhancers and (2) increased RNA expression in fetal naïve T cells relative to adult naïve T cells. 
Genes assessed for protein expression in (E) highlighted in bold.  
(D) Intersect of Treg-specific genes associated with: (1) increased H3K27ac signal at Treg-
accessible enhancers and (2) increased RNA expression in fetal naïve T cells relative to adult 
naïve T cells. Genes assessed for protein expression in (E) highlighted in bold.  
(E) Differential protein expression of Helios is present in fetal naïve T cells relative to adult naïve 
T cells. Flow cytometry plots (right) show staining intensity of Helios (IKZF2), Eos (IKZF4), 
CCR4, and FOXP3 in gated CD4+CD25-CD27+CD45RA+ adult (blue) and fetal naïve (red) cells. 
Staining intensity for isotype controls for Eos are shown in grey.  Mean fluorescence intensity 
was quantified, scaled, and plotted as a heatmap (right) for fetal (n=2) and adult (n=3) naïve T 
cells.  
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Figure 13. Fetal naïve T cells do not have an increased proportion of CD31+ recent 
thymic emigrants (RTE) relative to adult naïve T cells. 
(A) Gating strategy for defining CD31+ RTEs based on magnetically sorted CD4+ adult T cells. 
The CD31 positive gate was set by excluding the negative population defined in combination by 
the isotype staining control, effector memory (TEM) and central memory (TCM) populations.  
(B) Fetal naïve T cells do not have an increased proportion of RTEs as defined by CD31. Flow 
cytometry plots showing CD31 positive gating on sorted CD25-CD27+CD45RA+ naïve T cells 
from two representative fetal and adult samples (left). Boxplots show quantification of CD31+ 
RTE frequency (right) for adult (n=6) and fetal naïve T cells (n=8).  
(C) Fetal RTEs have decreased CD31 expression. Histogram (left) show CD31 staining within 
sorted naïve T cells for one representative fetal (green) and adult (blue) sample with an isotype 
staining control (grey). The RTE gate is outlined. Boxplots (right) show quantification of CD31 
mean fluorescence intensity of the CD31+ RTE population as gated in histogram for adult (n=6) 
and fetal (n=8). All statistics were calculated by unpaired two-sided Mann-Whitney test, *p<0.05, 
n.s. p>0.05. Boxplots show median (center line), interquartile range (box) and tenth and 
ninetieth percentiles (whiskers). 
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Figure 14. A fraction of fetal naïve T cells are highly proliferative.  
(A) Fetal naïve T cells are not activated at steady state. Representative flow cytometry plots 
(left) of one experiment show CD69 staining for sorted fetal and adult CD25-CD27+ CD45RA+ 
naïve T cells. Boxplot (right) quantifies (1) Helios-CD69+ (grey) and (2) Helios+CD69+ (red) 
quadrants as shown for fetal samples (n=6).  
(B) A fraction of fetal naïve T cells are actively proliferating. Representative flow cytometry plots 
of one experiment show Ki-67 staining for sorted fetal and adult naïve T cells.  
(C) The Helios+ fraction contains the majority of actively proliferating cells. Representative flow 
cytometry plots (left) of one experiment gating for Ki-67 expression within Helios- and Helios+ 
fractions within fetal naïve T cells. Boxplot (right) quantifies the percentages of Ki67+ cells 
shown in the flow cytometry plots. All statistics were calculated by two-sided Wilcoxon signed-
rank test, *p<0.05, n.s. p>0.05. Boxplots show median (center line), interquartile range (box) 
and tenth and ninetieth percentiles (whiskers). 
(D) Fetal and adult naïve T cells both highly upregulate Ki-67 by Day 5 of stimulation. Sorted 
fetal and adult naïve T cells stimulated with αCD3/αCD28/αCD2 tetramers and IL-2 alone over 
1, 3 and 5 days. Flow cytometry plots are representative of one experiment for live, CD4+ cells. 
Positive gate defines the Ki-67hi population.  
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Figure 15. Fetal naïve T cells do not have demethylation at the FOXP3 CNS2 (conserved 
non-coding sequence 2) Treg-specific demethylated region (TSDR). 
Sorted fetal and adult ex vivo naïve and Treg cells, along with differentiated in vitro induced Treg -
(iTreg) cells, were assessed for CpG demethylation at the FOXP3 CNS2 TSDR locus.  
(A) Fetal and adult naïve T cells show no difference in the extent of CpG demethylation at the 
TSDR. Heatmap shows percentage methylation of CpGs 34-42 at the FOXP3 CNS2, defined as 
2263-2330 basepairs upstream of the ATG start codon. More information on sequenced 
populations are in Supplementary Materials and Methods. 
(B) Flow cytometry plots from one representative adult iTreg sample differentiated in IL-2 and 
TGFβ showing gating strategy for fluorescence activated cell sorting (FACS) of (1) FOXP3-, (2) 
FOXP3+Helios- and (3) FOXP3+Helios+ populations.  
(C) Flow cytometry plots show purity of sorted FOXP3- and FOXP3+Helios- populations for one 
representative adult iTreg sample differentiated in IL-2 and TGFβ. 
(D) Flow cytometry plots show FOXP3 staining within sorted FOXP3-, FOXP3+Helios- and 
FOXP3+Helios+ populations for one representative fetal iTreg sample differentiated in IL-2 alone 
(top row) or in IL-2 and TGFβ (bottom row).  
(E) Flow cytometry plots show Helios staining within sorted FOXP3+Helios- and FOXP3+Helios+ 
populations for one representative fetal iTreg sample differentiated in IL-2 alone (top row) or in IL-
2 and TGFβ (bottom row).  
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Figure 16. Helios+ fetal induced Treg cells have increased FOXP3 expression 
Sorted fetal and adult naïve T cells were stimulated with αCD3/αCD28/αCD2 tetramers and IL-2 
in the absence or presence of TGFβ over 1, 3 or 5 days, and analyzed by flow cytometry. The 
number of biological replicates for each time point and stimulation condition are specified in 
table S8.  
(A) Fetal naïve T cells, but not adult naïve T cells, rapidly upregulate Helios and FOXP3 upon T 
cell receptor stimulation. Representative flow cytometry plots show Treg induction in the 
presence of IL-2 and TGFβ for fetal (top) and adult (bottom) naïve T cells respectively gated on 
live, CD4+ T cells.  
(B) Fetal induced Treg (iTreg) cells, and not adult iTreg cells, retain Helios expression. 
Quantification of percentage of Helios+FOXP3+ iTreg cells gated in (A) for adult (AN) and fetal 
naïve (FN) T cells stimulated in the presence or absence of TGFβ. Statistics calculated using 2-
way ANOVA with Tukey’s honest significant difference post-test, ***p<0.001. Error bars denote 
mean ± s.d. 
(C) The Helios+ population contains the majority of the fetal iTreg cells. Representative flow 
cytometry plots shown for one fetal sample stimulated with IL-2 and TGFβ at day 1.  
(D) Quantification of the proportion of fetal Treg cells in the Helios+ or Helios- population as gated 
in (C) over 1, 3 and 5 days in the absence (left) or presence (right) of TGFβ.  
(E) FOXP3 mean fluorescence intensity was increased in Helios+ iTreg cells relative to Helios- 
iTreg cells as gated in (C) across all time points in the absence (left) or presence (right) of TGFβ. 
Statistics for (D,E) were calculated by two-sided Wilcoxon signed-rank test, ***p<0.001, 
**p<0.01, *p<0.05. All boxplots show median (centre line), interquartile range (box) and tenth 
and ninetieth percentiles (whiskers) 
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Figure 17. Fetal naïve T cells upregulate Helios during Treg induction. 
Fetal and adult naïve T cells were stimulated with αCD3/αCD28/αCD2 tetramers and IL-2 in the 
presence or absence of TGFβ. The numbers of biological replicates for each time point and 
stimulation condition are specified in table S8. Cells were analysed by flow cytometry at 1, 3 and 
5 days.  
(A) A larger fraction of fetal naïve T cells differentiate into Treg cells relative to adult naïve T cells 
over 1,3 or 5 days of T cell receptor stimulation. Representative flow cytometry plots are shown 
for one experiment for live, CD4+ T cells. 
(B) Quantification of percentages of induced Treg (iTreg) gated in (A) for adult (AN) and fetal (FN) 
cells.  
(C) A large fraction of fetal naïve T cells upregulate and maintain Helios expression over all time 
points. Representative flow cytometry plots are shown for one experiment for live, CD4+ T cells. 
Helios+ and Helios- gates were set to staining levels of adult naïve T cells at day 1. 
(D) Quantification of percentages of Helios+ cells gated in (C) for AN and FN cells.  
All statistics were calculated with 2-way ANOVA with Tukey’s HSD post-test, ***p<0.001, n.s. 
p>0.05. Error bars denote mean ± s.d. 
(E) Fetal and adult naïve T cells increase Ki-67 expression to the same extent after proliferation 
regardless of Helios expression. Representative flow cytometry plots of one experiment show 
Ki-67 and Helios staining for live, CD4+ cells. 
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Figure 18. Validation of CRISPR-Cas9 editing at the Helios locus 
Primers amplifying across cut sites for gRNA1 and gRNA2 were used to amplify the Helios locus 
and were sequenced. Sequencing traces were analyzed with the Tracking of Indels by 
DEcomposition (TIDE) webtool (http://tide.nki.nl/) to verify editing.  
(A) Histogram shows percentage of sequence aberration found comparing sequencing 
chromatograms of amplicons from cells treated with the non-targeting (NT) gRNA and Helios 
gRNA1 (left) or gRNA2 (right). The blue line shows the predicted cut site; the region following 
the cut site was used for decomposition by TIDE.  
(B) Chromatograms of amplicons from NT gRNA (top) and gRNA1 (bottom) nucleofections. The 
full sequence of gRNA1 is highlighted in blue, and black lines denote the TIDE predicted cut 
site. Frameshifts in the sequence resulting in jumbled sequences after the cut site were only 
observed with gRNA1 mediated editing.   
(C) Chromatograms of amplicons from NT gRNA (top) and gRNA2 (bottom) nucleofections. The 
full sequence of gRNA2 is highlighted in blue, and black lines denote the TIDE predicted cut 
site. Frameshifts in the sequence resulting in jumbled sequences after the cut site were only 
observed with gRNA2 mediated editing.   
(D) Assessment of efficiency of Helios editing by intracellular flow cytometry. Efficiency was 
calculated by taking the percentage of Helios+ cells gated in gRNA-edited cells divided by 
percentage of Helios+ in NT controls. Boxplot shows percentage efficiency for gRNA1 and 2 
across both stimulation conditions at day 6 post-editing. Statistics were calculated by unpaired 
two-sided Mann-Whitney test, n.s. p>0.05. 
(E) Flow cytometry plots show adult iTreg cells which received NT, gRNA1 and gRNA2 guides 
used to set CD25hiFOXP3hi Treg gates for two different representative donors. 
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Figure 19. CRISPR-Cas9 mediated knockout of Helios in fetal naïve T cells reduces their 
preferential differentiation into Treg cells. 
(A) Schematic showing experimental design. CRISPR-Cas9 editing at the Helios locus with two 
independent guide RNAs (gRNA1, gRNA2, see Supplementary Materials & Methods) was 
carried out in pre-stimulated fetal naïve T cells, with a non-targeting (NT) gRNA as a control. 
Edited cells were stimulated with αCD3/αCD28/αCD2 tetramers in the absence or presence of 
TGFβ. Treg induction was assessed at 6 days. The numbers of biological replicates for each 
guide and stimulation condition are specified in table S9.   
(B) CRISPR-Cas9 editing at the Helios locus reduces Helios expression in fetal naïve T cells 
relative to the non-targeting (NT) guide as evaluated by intracellular flow cytometry. 
Representative plots of one experiment are shown gated on live, CD4+ T cells. 
(C) Quantification of Helios expression post-editing in fetal naïve T cells after Treg induction as in 
(B). Boxplots show paired samples for gRNA1 (left) and gRNA2 (right).  
(D) Helios ablation in fetal naïve T cells reduces Treg induction in response to TCR signaling 
alone. This effect was abolished by the addition of TGFβ. Representative plots of one 
experiment are shown gated on live, CD4+ T cells.  
(E) Quantification of induced Treg proportions in edited fetal naïve T cells as in (D). Boxplots 
show paired samples for gRNA1 (left) and gRNA2 (right). All statistics were calculated by two-
sided Wilcoxon signed-rank test, ***p<0.001, **p<0.01, *p<0.05. All boxplots show median 
(center line), interquartile range (box) and tenth and ninetieth percentiles (whiskers). 
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Figure 20. The effect of CRISPR-Cas9 knockout of Helios on protein expression of Treg 
functional markers is variable. 
(A) The reduction in Treg differentiation in fetal naïve T cells differentiated in response to TCR 
signaling alone is correlated with the difference in Helios percentage after editing. Scatterplots 
show correlation between the difference in percentages of CD25hiFOXP3hi Treg against the 
difference in percentages of Helios+ T cells for cells edited with gRNA1 (left) or gRNA2 (right) 
versus NT gRNA.  
(B) The reduction in Treg differentiation in fetal naïve T cells differentiated in IL-2 and TGFβ is not 
correlated with the difference in Helios percentage after editing. Scatterplots show correlation 
between the difference in percentages of CD25hiFOXP3hi Treg against the difference in 
percentages of Helios+ T cells for cells edited with gRNA1 (left) or gRNA2 (right) versus NT 
gRNA. Adjusted R2 and p values for (A,B) were calculated by simple linear regression, n.s., 
p>0.05. 
CRISPR-Cas9 editing of the Helios locus with gRNA1 (left), gRNA2 (right) had no effect on the 
mean fluorescence intensity (MFI) of (C) FOXP3, (D) CD25 in comparison to the NT control in 
fetal iTreg cells. MFI of (E) CTLA-4 is reduced in edited fetal induced Treg (iTreg) cells treated with 
Helios gRNA compared to NT controls. Boxplots show MFI of live, CD4+ T cells 6 days post 
induction in the presence of absence of TGFβ.  
(F) Helios knockout may reduce upregulation of GARP and LAP in fetal iTreg cells. 
Representative flow cytometry plots shown for one experiment for live, CD4+CD25hiFOXP3hi Treg 
cells differentiated in the presence (top) or absence (bottom) of TGFβ.  
(G) Quantification of GARP+LAP+ fetal iTreg cells after Helios knockout as in (F) for cells treated 
with gRNA1 (top) or gRNA2 (bottom). All statistics for (C, D, E, G) were calculated by two-sided 
Wilcoxon signed-rank test, ***p<0.001, *p<0.05, n.s. p>0.05. All boxplots show median (centre 
line), interquartile range (box) and tenth and ninetieth percentiles (whiskers). 
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Figure 21. Fetal, but not adult, induced Treg cells have suppressed IL-2 production after 
restimulation 
Fetal and adult iTreg differentiated with IL-2 in the presence or absence of TGFβ for 5 days were 
restimulated with Phorbol 12-Myristate 13-Acetate (PMA), ionomycin, and Brefeldin A for 5 
hours to measure cytokine production.  
(A) Fetal induced Treg (iTreg) cells have reduced IL-2 production upon restimulation. Flow 
cytometry plots show staining for intracellular IL-2 in unstimulated controls (top) in comparison 
to restimulated cells (bottom). Plots show one representative experiment for fetal and adult iTreg 
cells differentiated with IL-2 alone gated on live CD4+ T cells.  
(B) Quantification of IL-2 production in fetal and adult iTreg cells after restimulation in (A) after 
Treg induction in IL-2 alone (fetal, n=22, adult, n=8) or with added TGFβ (fetal, n=19, adult, n=9). 
Statistics calculated with unpaired two-sided Mann-Whitney test, ***p<0.001, *p<0.05, n.s., 
p>0.05.   
(C) Reduction of IL-2 production is greater in Helioshi fetal iTreg population. Flow cytometry plots 
show staining for intracellular IL-2 in unstimulated controls (top) and restimulated fetal iTreg 
differentiated in IL-2 alone (center) and in the presence of added TGFβ (bottom) for one 
representative experiment gated on live CD4+ T cells.  
(D) Helioshi iTreg cells produce more IL-2 than Helios+ iTreg cells. Flow cytometry plots show gating 
for Helioshi and Helioslo populations, after staining for intracellular IL-2 was assessed for one 
representative sample cultured in IL-2 alone. Boxplots show quantification for Helioslo (grey) and 
Helioshi (red) fetal iTreg differentiated in IL-2 alone (n=22) or with TGFβ added (n=19). Statistics 
calculated by two-sided Wilcoxon signed-rank test, ** p<0.01, *p<0.05. 
(E) The ablation of Helios expression in fetal iTreg cells result in increased IL-2 production 
regardless of induction condition. Histograms show gating for one representative sample 
cultured in IL-2 alone (right) and with added TGFβ (left) for live CD4+ T cells.  
(F) Quantification of IL-2 after Helios ablation by CRISPR editing as in (E) for iTreg cells 
differentiated in IL-2 alone or with added TGFβ (NT, n = 16, sgRNA1, n=14, sgRNA2, n = 16 for 
both stimulation conditions). Statistics calculated by two-sided Wilcoxon signed-rank test, 
**p<0.01, *p<0.05. All boxplots show median (centre line), interquartile range (box) and tenth 
and ninetieth percentiles (whiskers). 
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Figure 22. Helios knockout in fetal iTreg cells result in a subtle shift in the underlying 
transcriptome 
(A) Paired lineplots quantify differences in Helios expression measured by flow cytometry in 
fetal iTreg cells nucleofected with Helios gRNA1 (HeliosKO) relative to the non-targeting control 
(HeliosWT) in the presence of IL-2 alone or with exogenous TGFβ. Samples sequenced shown in 
red (n=6). (B) Principal component analysis (PCA) reveals a subtle separation of HeliosKO and 
HeliosWT populations. Three-dimensional PCA plot show separation of populations first by Treg 
differentiation conditions (Principal component, PC1, IL-2 versus IL-2 and TGFβ), and then by 
the absence or presence of Helios knockout (PC2, 3, HeliosKO vs HeliosWT).  
(C) Two-dimensional PCA plot of PC1 and PC2 shown in (B) show that PC2 segregates 
HeliosWT and HeliosKO iTreg cells differentiated in the presence of TGFβ. Boxplots show scores 
for PC1 and 2 (bottom and right respectively). 
(D) Two-dimensional PCA plot of PC1 and PC3 shown in (B) show that PC3 segregates 
HeliosWT and HeliosKO iTreg cells differentiated in the absence of TGFβ. Boxplots show scores for 
PC1 and 2 (bottom and right respectively).  
(E,F) Changes in the overall transcriptome in HeliosKO relative to HeliosWT iTreg cells are modest 
but detectable in both differentiation conditions. Scatterplots plots log2FC values for 
comparisons for the absence or presence of exogenous TGFβ during the differentiation process 
(y axis) and HeliosKO against HeliosWT iTreg (x axis) that underwent differentiation in IL-2 alone 
(E) or with exogenous TGFβ added (F). Dotted lines in grey denote log2FC cut-offs. Genes with 
false discovery rate (FDR) <0.05 and fold change (FC) > 1.1 are in dark grey, with top ten genes 
with the highest fold changes in both conditions labeled.  
(G) HeliosWT iTreg cells have increased IL10 transcription over HeliosWT cells. Boxplots show 
trimmed mean of M values of log2 normalized RNAseq reads for IL10. All boxplots show median 
(centre line), interquartile range (box) and tenth and ninetieth percentiles (whiskers).  
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Figure 23. Ablation of Helios in fetal iTreg results in downregulation of Treg-specific genes, 
and the concurrent upregulation of pro-inflammatory genes.  
CRISPR-Cas9 editing was carried out in fetal naïve T cells (n=6) with Helios gRNA1 (HeliosKO) 
or the non-targeting control guide (HeliosWT). Edited cells stimulated with αCD3/αCD28/αCD2 
tetramers in the absence or presence of TGFβ for 6 days, after which changes in their overall 
transcriptome was assessed by RNAseq.  
(A) Helios ablation results upregulation of pro-inflammatory genes and downregulation of genes 
associated with Treg phenotype and function in parallel or addition to TGFβ signaling. Scatterplot 
plots log 2 fold change (log2FC) values comparing the absence or presence of exogenous TGFβ 
during the differentiation process (y-axis) and HeliosKO against HeliosWT iTreg (x-axis) that 
underwent differentiation in IL-2 alone (left, IL-2 only iTreg) or with exogenous TGFβ added (right, 
IL-2 + TGFβ-iTreg). Dotted lines in grey denote log2FC cut-offs. Genes upregulated (dark purple) 
or downregulated (dark orange) in HeliosKO relative to HeliosWT iTreg cells are colored (fold 
change, FC>1.1,false discovery rate, FDR<0.05). Genes associated with Treg or pro-
inflammatory immune functions are outlined and labeled.  
(B) Helios controls the transcription of a core set of Treg-specific genes across both stimulation 
conditions. Scatterplot plots are similar to (A) for IL-2 only iTreg cells (left) and IL-2 + TGFβ-iTreg 
(right). Shared genes meeting cutoffs (FC>1.1, FDR<0.05) that were upregulated (light purple) 
or downregulated (light orange) in HeliosKO relative to HeliosWT iTreg cells are colored. Genes 
associated with Treg or pro-inflammatory immune functions within the shared Helios-regulated 
transcriptome are outlined and labeled.  
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Figure 24. Fetal Helios knockout iTreg cells have decreased IL-10 and increased IFNγ 
cytokine production. 
 (A) Fetal, but not adult iTreg cells produce IL-10 during iTreg differentiation. Boxplots quantify IL-
10 cytokine concentration within culture supernatants collected at day 3 and 5 of differentiation 
for adult (blue, n=27) or fetal iTreg cells (orange, n=58) differentiated in IL-2 alone (IL-2 iTreg), as 
well as adult (light blue, n=27) or fetal (light orange, n=55) iTreg cells differentiated with added 
TGFβ (TGFβ-iTreg).  
(B) Fetal iTreg cells suppress IFNγ production over the course of iTreg differentiation. Boxplots 
quantify IFNγ cytokine concentrations for samples as in (A).  
(C) Fetal TGFβ-iTreg cells produce more IL-10 than IFNγ. Boxplots show log2(n+1) ratio of IL-10 
to IFNγ cytokine concentration for samples as in (A). Dotted line marks the ratio at which cells 
produce IL-10 and IFNγ at 1:1. All statistics for (A,B,C) calculated by unpaired two-sided Mann-
Whitney test,*** p<0.001, ** p<0.01, *p<0.05.  
(D) Helios ablation reduces IL-10 production by fetal IL-2-iTreg cells. Boxplots quantify IL-10 
cytokine concentrations at day 5 of differentiation for iTreg cells that received the non-targeting 
guide (HeliosWT, red) or for Helios knockout (HeliosKO, blue) with gRNA1 (left, n=24) and gRNA2 
(right, n=23).  
(E) Helios ablation increases IFNγ production in fetal TGFβ-iTreg cells. Boxplots quantify IFNγ 
cytokine concentrations for samples in (D).  
(F) Helios ablation tips the balance from immunosuppressive IL-10 towards pro-inflammatory 
IFNγ production in fetal iTreg cells. Boxplots show log2(n+1) ratio of IL-10 to IFNγ cytokine 
concentration for samples as in (D). Dotted line marks the ratio where cells produce IL-10 and 
IFNγ at 1:1. All statistics for (D,E,F) calculated by two-sided Wilcoxon signed-rank test, *** 
p<0.001, * p<0.05, n.s. p>0.05. All boxplots show median (centre line), interquartile range (box) 
and tenth and ninetieth percentiles (whiskers). 
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Table 2.7.3. Statistics	from	GSEA	testing	
Fetal versus adult iTreg cells differentiated in IL-2 alone 
GENESET 
NAME 
SIZE ES NES FDR 
q-val 
LEADING 
EDGE 
RANK 
AT 
MAX 
NOM 
p-val 
FWER 
p-val 
GSE7460_ 
TREG_VS_ 
TCONV_ACT_
UP 
169 0.64 1.66 6.30E
-03 
tags=22%, 
list=7%, 
signal=23% 
907 4.13E-
04 
6.00E-
03 
UP_IN_ 
HUMAN_ 
MTREG 
142 0.64 1.64 4.52E
-03 
tags=50%, 
list=13%, 
signal=57% 
1751 7.06E-
04 
8.50E-
03 
GSE7460_TRE
G_VS_TCONV
_ACT_WITH_T
GFB_UP 
134 0.60 1.51 2.46E
-02 
tags=25%, 
list=9%, 
signal=27% 
1205 8.89E-
03 
6.53E-
02 
UP_IN_ 
HUMAN_ 
NTREG 
55 0.65 1.48 2.65E
-02 
tags=42%, 
list=7%, 
signal=45% 
935 3.50E-
02 
9.38E-
02 
CLUSTER 1.2 108 0.62 1.54 2.84E
-02 
tags=27%, 
list=8%, 
signal=29% 
1067 9.22E-
03 
3.73E-
02 
DOWN_IN_ 
HUMAN_ 
MTREG 
152 -0.61 -1.78 5.62E
-04 
tags=33%, 
list=8%, 
signal=35% 
1084 0.00E+
00 
9.00E-
04 
CLUSTER 1.3 50 -0.75 -1.86 0.00E
+00 
tags=38%, 
list=8%, 
signal=41% 
1131 0.00E+
00 
0.00E+
00 
Fetal versus adult iTreg cells differentiated in IL-2 and TGFβ 
GENESET 
NAME 
SIZE ES NES FDR q-
val 
LEADING 
EDGE 
RANK 
AT 
MAX 
FWER 
p-val 
NOM 
p-val 
UP_IN_ 
HUMAN_ 
NTREG 
55 0.77 1.77 1.13E-
03 
tags=49%, 
list=8%, 
signal=53% 
1122 1.10E-
03 
6.54E-
04 
UP_IN_ 
HUMAN_ 
MTREG 
142 0.64 1.66 4.80E-
03 
tags=53%, 
list=13%, 
signal=60% 
1737 9.90E-
03 
4.39E-
04 
GSE7460_TR
EG_VS_TCO
NV_ACT_UP 
169 0.55 1.45 4.60E-
02 
tags=22%, 
list=7%, 
signal=24% 
901 1.31E-
01 
1.51E-
02 
GENESET 
NAME 
SIZE ES NES FDR q-
val 
LEADING 
EDGE 
RANK 
AT 
MAX 
NOM 
p-val 
FWER 
p-val 
CLUSTER 1.2 108 0.62 1.55 2.54E-
02 
tags=29%, 
list=8%, 
signal=31% 
1033 3.27E-
02 
8.55E-
03 
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CLUSTER 1.1 114 0.58 1.47 3.21E-
02 
tags=33%, 
list=10%, 
signal=37% 
1442 8.00E-
02 
2.37E-
02 
DOWN_IN_ 
HUMAN_ 
MTREG 
152 -0.64 -1.85 6.16E-
05 
tags=41%, 
list=11%, 
signal=46% 
1464 1.00E-
04 
0.00E+
00 
CLUSTER 1.3 50 -0.79 -1.93 2.38E-
04 
tags=38%, 
list=8%, 
signal=41% 
1147 1.00E-
04 
2.52E-
04 
CLUSTER 1.4 52 -0.65 -1.61 5.37E-
03 
tags=33%, 
list=7%, 
signal=35% 
901 7.60E-
03 
8.22E-
03 
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Table 2.7.7 Top Shared superenhancers between adult naïve, adult Treg and fetal naïve T cell 
Cell Type  GeneID enhancerRank EnrichSignal 
Adult Treg FAM53B 1 90338.9016 
Adult Treg BCL11B 2 88642.2576 
Adult Treg RALGDS 3 64304.3212 
Adult Treg DAD1 4 63653.2075 
Adult Treg MYH9 5 60492.6471 
Adult Treg CCDC88C 6 60475.5936 
Adult Treg NCK2 7 59680.5552 
Adult Treg MIR4632 8 57337.7156 
Adult Treg HIVEP2 9 55030.746 
Adult Treg PHF19 10 54694.6618 
Adult Treg MIR3188 11 52317.5121 
Adult Treg MIR4316 12 52256.4735 
Adult Treg IRF1 13 51019.5564 
Adult Treg KLF13 14 49691.2472 
Adult Treg MOB3A 15 49002.3585 
Adult Treg SEMA4D 16 48454.0416 
Adult Treg ANKRD44 17 48299.398 
Adult Treg MIR29A 18 47766.4477 
Adult Treg RARA 19 47397.6506 
Adult Treg SKI 20 45210.7782 
Adult Treg RHOH 21 45002.461 
Adult Treg FAM107B 22 44423.1774 
Adult Treg ETS1 23 44146.8885 
Adult Treg RAPGEF1 24 43940.3737 
Adult Treg CELF2 25 43713.0204 
Adult Naïve BCL11B 1 63863.2072 
Adult Naïve HIVEP2 2 46193.8302 
Adult Naïve ITPKB 3 39119.603 
Adult Naïve CCR7 4 38740.2096 
Adult Naïve ETS1 5 35402.6181 
Adult Naïve KLF13 6 33468.4465 
Adult Naïve MIR4316 7 33431.275 
Adult Naïve DAD1 8 32912.275 
Adult Naïve MYH9 9 31014.6954 
Adult Naïve RHOH 10 29338.9504 
Adult Naïve ADGRE5 11 28999.8467 
Adult Naïve CD247 12 28462.6503 
Adult Naïve CRIP1 13 27972.432 
Adult Naïve LEPROTL1 14 27798.9002 
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Cell Type  GeneID enhancerRank EnrichSignal 
Adult Naïve MOB3A 15 27160.3896 
Adult Naïve KDM6B 16 26527.4289 
Adult Naïve CCDC88C 17 26451.0077 
Adult Naïve MIR3188 18 25147.0695 
Adult Naïve ZFP36L2 19 25009.6167 
Adult Naïve PER1 20 23827.7492 
Adult Naïve NCK2 21 23032.646 
Adult Naïve TCF7 22 22649.3449 
Adult Naïve LRRFIP1 23 22335.3472 
Adult Naïve PITPNC1 24 22171.8928 
Adult Naïve NEAT1 25 22154.526 
Fetal Naïve BCL11B 1 62343.7038 
Fetal Naïve ETS1 2 48234.8667 
Fetal Naïve KLF13 3 45096.9791 
Fetal Naïve ITPKB 4 44268.8808 
Fetal Naïve RHOH 5 42130.726 
Fetal Naïve MIR4316 6 41956.7058 
Fetal Naïve DAD1 7 39631.488 
Fetal Naïve MYH9 8 39038.6605 
Fetal Naïve CHIT1 9 37766.114 
Fetal Naïve ADGRE5 10 37329.1296 
Fetal Naïve CD247 11 37142.628 
Fetal Naïve NEAT1 12 35427.2636 
Fetal Naïve MIR4492 13 34963.1721 
Fetal Naïve BACH2 14 33860.3712 
Fetal Naïve PTPRC 15 32658.696 
Fetal Naïve KDM6B 16 32127.0662 
Fetal Naïve LRRFIP1 17 31812.7375 
Fetal Naïve LEPROTL1 18 31129.635 
Fetal Naïve TCF7 19 30975.966 
Fetal Naïve PLEC 20 29933.813 
Fetal Naïve SKI 21 29440.3344 
Fetal Naïve CYTIP 22 28938.1605 
Fetal Naïve RARA 23 28142.8194 
Fetal Naïve EVL 24 27667.328 
Fetal Naïve NCK2 25 27386.0205 
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Table 2.7.8 Experimental setup for Treg induction time course carried out for adult and fetal 
naïve T cells. 
 
Cell origin Stimulation 
condition 
Day Number of biological 
replicates 
Fetal IL-2 1 8 
 TGFβ 1 5 
Adult IL-2 1 7 
 TGFβ 1 5 
Fetal IL-2 3 11 
 TGFβ 3 7 
Adult IL-2 3 8 
 TGFβ 3 6 
Fetal IL-2 5 5 
 TGFβ 5 5 
Adult IL-2 5 7 
 TGFβ 5 6 
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Table 2.7.9.  Experimental setup for Helios CRISPR-Cas9 mediated editing for subsequent Treg 
induction carried out for fetal naïve T cells. 
 
Stimulation 
condition 
Guide Number of biological 
replicates 
IL-2 Non-targeting 39 
IL-2 gRNA1 38 
IL-2 gRNA2 33 
TGFβ Non-targeting 36 
TGFβ gRNA1 36 
TGFβ gRNA2 32 
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CHAPTER 3 – MATERIALS AND METHODS 
Material for this chapter was modified from a manuscript currently in revision: 
Ng MSF, Roth TL, Mendoza VF, Marson A, Burt TD. Helios predisposes human fetal CD4+ 
naïve T cells towards regulatory T cell differentiation. 2019 (in revision) 
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3.1 Study design 
The objective of this study was to determine the molecular mechanisms that underlie 
preferential Treg cell differentiation in human fetal naïve T cells. As such, primary human CD4+ 
naïve T and Treg cells from fetal spleen and adult peripheral blood mononuclear cells were the 
primary cell sources used for this study. Transcriptional and epigenetic profiling was carried out 
utilizing RNAseq, H3K27ac ChIPseq and ATACseq. Flow cytometry was utilized to confirm 
observations from sequencing datasets, to validate of expression levels at baseline, and to 
assess the activation and subsequent differentiation of fetal and adult naïve T cells in in vitro 
experiments. CRISPR-mediated knockout was used to confirm the results of the observational 
studies. The sample size (n = 2-6) for the sequencing datasets was determined to be the 
optimal size for statistical analysis and to allow for independent repeats, given the scarcity of 
tissue available for fetal samples. The sample size and experimental replicates for in vitro 
experiments are subsequently indicated all accompanying figure legends. Sample size was 
determined to be adequate based on the magnitude and consistency of measurable differences 
between groups. Investigators were not blinded, and samples were equally divided between 
treatments, i.e. gRNA received.  
 
3.2 Cell isolation and purification 
Fetal splenocytes were obtained under the auspices of the UCSF Committee on Human 
Research (CHR) at 18-23 gestational weeks from the Department of Obstetrics, Gynecology 
and Reproductive Science, San Francisco General Hospital. Global consent for research was 
obtained by medical providers, medical information abstracted, and any Personal Health 
Information removed prior to any contact with researchers. Samples were transported in media 
on ice and processed within 2-3 hours after collection. Tissue was mechanically dispersed and 
digested with 3mg/ml Collagenase IV (Life Technologies) and 1mg/ml DNAse (Roche) in RPMI-
98
1640 supplemented with 10% HI-FBS (heat inactivated fetal bovine serum), 300mg/mL L-
glutamine, 10U/mL Penicillin, and 10ug/mL Streptomycin (supplemented RPMI) for 30 minutes 
in shaking water bath. Single cell suspensions were created by passage through a 70uM filter, 
and the lymphocyte fraction was isolated by density centrifugation of a Ficoll-Hypaque gradient 
(Amersham Biosciences). Residues from TRIMA Apheresis collection kits were obtained from 
the Blood Centers of the Pacific (San Francisco, CA), and adult peripheral blood mononuclear 
cells (PBMCs) were similarly isolated by density centrifugation. All samples were either utilized 
immediately post isolation or viably cryopreserved prior to use. No difference in function or 
phenotype was detected in samples before and after cryopreservation.  
 
3.3 Magnetic isolation of CD4+ T cells and fluorescence activated cell sorting (FACS) for 
sequencing and cell culture 
Prior to FACS, fetal splenocytes and adult PBMCs were pre-enriched for CD4+ T cells using the 
EasySep Human CD4+ T cell isolation kit (#17952, Stemcell Technologies) according to the 
manufacturer’s instructions. In order to obtain sufficient numbers of adult regulatory T (Treg) cells 
for epigenetic analyses, adult PBMCs were also pre-enriched for CD4+CD127lo T cells using the 
Human CD4+CD127lo T cell Pre-enrichment kit (#19231, Stemcell Technologies). Enriched cell 
fractions were then incubated in FACS staining buffer (Phosphate buffered saline, PBS, with 2% 
HI-FBS and 2mM EDTA) with flurochrome-conjugated anti-human surface monoclonal 
antibodies (mAbs). Antibodies used include: CD25 FITC (2A3, BD Biosciences), CD127 
PE/BV421 (hIL-7R-M21, BD Pharmingen), CD45RA PE-CF594 (HI100, BD Horizon), CD4 PE-
Cy7 (SK3, BD Pharmingen), CD27 eFluor780 (O323, ThermoFisher Scientific). All cells were 
stained with the live-dead marker (GhostDye Violet 510; Tonbo Biosciences) to exclude dead 
cells. Cells were sorted into supplemented RPMI (10% HI-FBS, 300mg/mL L-glutamine, 10U/mL 
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Penicillin, and 10ug/mL Streptomycin) based on gating in Supplementary Figure 1. All cells were 
sorted on a BD FACS Aria III.  
 
3.4 RNA sequencing for ex vivo sorted cells 
RNAseq was carried out for 4 biological replicates of adult and fetal naïve and Treg cells, with 
2.5x105 cells per sample. RNA was extracted and purified with the Nucleospin RNA kit 
(Machery-Nagel) and assessed for quality by RNA Pico (Agilent Technologies). Library 
preparation and sequencing on a HiSeq300 were carried out by the Technology Center for 
Genomics and Bioinformatics  (TCGB) core at University of California, Los Angeles. 50bp 
single-end reads were aligned to hg19 using Bowtie2, and read counts per gene were obtained 
using RSEM. The EdgeR package for Bioconductor (113, 114) was utilized to perform TMM 
normalization and differential expression analysis of samples, with each pairwise comparison 
performed. TMM normalized reads were pre-filtered prior to PCA analysis, where genes with 
read counts less than one in three or more replicates of all cell types were removed from 
analysis.  PCA analysis was carried out in R using the prcomp function on log2(n+1) transformed 
TMM normalized reads. Differentially expressed genes were identified from pairwise 
comparisons between all four populations as meeting the following cutoffs: false discovery rate 
(FDR) <0.05 and log2 fold change (log2FC) >1.5. The Treg transcriptional signature is defined 
from the intersection of genes meeting the cutoffs above with increased/decreased transcription 
in pairwise comparisons of adult and fetal Treg populations against adult naïve T cells.  
 
3. 5 RNA sequencing for adult and fetal induced Treg populations 
4 biological replicates of sorted adult or fetal naïve T cells were stimulated in U-bottomed 96 
wells with 5ul of Immunocult Human T cell Activator (CD3/CD28/CD2 tetramers, Stemcell 
Technologies) in 200ul of culture media (RPMI-1640 supplemented with 10% HI-FBS (heat 
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inactivated fetal bovine serum), 300mg/mL L-glutamine, 10U/mL Penicillin, and 10ug/mL 
Streptomycin, 10mM HEPES, 1X MEM-NEAA, β-mercaptoethanol). Exogenous IL-2 (10ng/ml, 
Peprotech) and TGFβ (50ng/ml, Peprotech) were added according to the relevant experimental 
setup. 100ul media changes were performed every two days starting from the first day of 
stimulation. At day 6 post-induction, RNA from 2.5x104 iTreg cells was extracted and purified with 
the Nucleospin XS RNA kit (Machery-Nagel) and assessed for quality by RNA Pico (Agilent 
Technologies). Ribosomal RNA was removed using the NEBNext® Poly(A) mRNA Magnetic 
Isolation Module (New England Biolabs), and library preparation was carried out using the 
NEBNext® Ultra™ II Directional RNA Library Prep Kit for Illumina® (New England Biolabs). 
Sequencing on a HiSeq4000 was carried out by the Center for Advanced Technology core at 
University of California, San Franscisco. 50bp single-end reads were aligned to hg19 using 
Bowtie2, and read counts per gene were obtained using RSEM. The EdgeR package (v3.24.3) 
for Bioconductor (113, 114) was utilized to perform TMM normalization and differential 
expression analysis of samples. Due to the multifactorial experimental design, a generalized 
linear model (gLM) design was specified: 
~Stimulation+Celltype+Stimulation:Celltype 
This allowed for the assessment of the effect of stimulation condition (Stimulation: IL-2, IL-2 + 
TGFβ), cell origin (Celltype: Adult or Fetal) and any possible interaction between the two factors. 
Negative binomial dispersion was estimated using the design specified, and genewise gLM was 
fit before likelihood ratio tests (LRTs) were utilized to determine differentially expressed genes. 
Differentially expressed genes were defined by FDR <0.05 log2F>1.5. For PCA analysis, log2 
TMM normalized reads were obtained with a prior count of 5. Reads were pre-filtered, where 
genes with read counts less than one in three or more replicates of all cell types were removed 
from analysis.  PCA analysis was carried out in R using the prcomp function.  
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3.6 Gene set enrichment analysis (GSEA) for pairwise fetal versus adult iTreg 
comparisons 
GSEA was carried out using the javaGSEA program (v2.0.9) using the pre-ranked option with 
default parameters. Pre-ranked genelists were generated separately for fetal versus adult iTreg 
comparisons that were differentiated with IL-2 only, or with added exogenous TGFβ. Genes 
were ranked by -log10(FDR) multiplied by the sign of the corresponding log2FC to determine 
directionality. Four genesets: GSE7460_TREG_VS_TCONV_ACT_DN, 
GSE7460_TREG_VS_TCONV_ACT_UP 
GSE7460_TREG_VS_TCONV_ACT_WITH_TGFB_DN, and 
GSE7460_TREG_VS_TCONV_ACT_WITH_TGFB_UP were obtained from the Molecular 
Signatures Database (MSigDB) from the C7 immunologic gene sets collection [cite Hill and 
MSigDB here]. Another four genesets were derived from microarrays (accession GSE76598) 
performed on CD4+CD4RA+ naïve and CD4+CD45RA- memory human CD25- conventional and 
CD25hi Treg cells activated for 40 hours with αCD3/αCD28 coated beads [cite Pensenacker et 
al.].  GEO2R (NCBI) was utilized to return associated FDR and adjusted p-values associated 
with all genes, and genesets used for GSEA were created by filtering genes by FDR<0.05 and 
log2FC>1.5 in both directions. Lastly, another four gene sets were defined from k-means 
clustering analysis on the Treg transcriptional signature defined from ex vivo sorted human fetal 
and adult naïve and Treg cells as detailed above. Normalized enrichment scores (NES) were 
used to compare between genesets. GSEA result outputs were plotted in R using the 
ReplotGSEA package [cite].  
 
3.7 Assay for transposase-accessible chromatin (ATACseq) 
ATACseq was performed as previously described (115, 116), for adult naïve, adult Treg and fetal 
naïve T cells. Fetal Treg cells were unable to be subjected to this assay due to limitation of cell 
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numbers. 5x104 sorted cells per sample were transposed with sequencing adapters using the 
Nextera DNA Library Prep kit (Illumina), and transposed chromatin purified with the MinElute 
PCR Purification Kit (Qiagen). Amplification cycles were first determined by quantitative PCR as 
described, and subsequently used to amplify prepared libraries using NEBNext High Fidelity 2X 
PCR Master Mix (New England Biolabs). Amplified libraries were then purified with the MinElute 
PCR Purification Kit (Qiagen). Sequencing was carried out on a HiSeq2500 (Institute for Human 
Genetics, UCSF). Sequence reads (25bp, paired-end) were mapped to hg19 using Bowtie2, and 
subsequently filtered for unique mappability (mapq ≥ 30). For the generation of Bigwig files, tag 
densities were calculated as the number of tags that map to within 75bp of each 20bp genomic 
bin. Tag insertion positions were calculated as +4bp from the upstream end of positive strand 
tags and -5 bp from negative strand tags. Blacklist regions were also removed using known 
regions from the ENCODE consortium using the bedtools –overlap function. Regions with tag 
density greater than 40 were identified as accessible regions.  
 
3.8 H3K27ac chromatin immunoprecipitation sequencing (ChIPseq) 
A modified protocol adapted from Collas et al. (117) and the truChIP protocol (Covaris) was 
utilized for 5x105 sorted cells per sample for adult naïve, adult Treg and fetal naïve T cells. Fetal 
Treg cells were unable to be subjected to this assay due to limitation of cell numbers. Cells were 
counted and washed in 500ul of cold PBS buffer. Cross-linking, quenching and lysis were 
performed with the truChIP Chromatin Shearing Kit with Formaldehye (Covaris) according to 
manufacturer’s instructions, with the addition of protease inhibitor cocktails and 20mM sodium 
butyrate (Sigma-Aldrich) to all buffers. Sonication was carried out with an AFA-Focused Covaris 
S2 ultrasonicator in AFA microtubes (Covaris) for 6 minutes (duty cycle 10%, intensity 5, cycle-
burst 200). Samples were subsequently diluted up to 1ml in RIPA buffer (10mM Tris-HCl pH 7.5, 
140mM NaCl, 1mM EDTA, 1% Triton-X, 0.01% SDS, 0.1% Na-deoxycholate, 1X protease 
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inhibitors, 20mM sodium butyrate), and 100ul was set aside for the input control. For H3K27ac 
ChIP, 5ug of αH3K27ac rabbit pAb (ab4729, Abcam) was incubated for 2 hours at 4oC with an 
equal mix of protein A and protein G beads. Antibody-bound beads were then washed twice with 
RIPA buffer. 900ul of sonicated chromatin was then added, and incubated overnight at 4oC on a 
rotator to maximize immunoprecipitation. Beads with bound chromatin were then sequentially 
washed in 1ml of the following buffers (with 1X protease inhibitors and 20mM sodium butyrate 
added for all buffers) for 5mins on the rotator at 4oC with: (1) Low-salt buffer (0.1% SDS, 1% 
Triton-X, 2mM EDTA, 20mM Tris-HCl, 150mM NaCl), (2) LiCl buffer (0.25M LiCl, 1% NP-40, 1% 
Na-deoxycholate, 1mM EDTA, 1mM Tris-HCl), (3) TE buffer (10mM Tris-HCl and 1mM EDTA). 
Input samples were similarly incubated overnight without antibody-bound beads and left on ice 
while beads were washed, and therefore treated similar to immunoprecipitation samples from 
this step onwards. All samples were treated with RNAse A (Sigma-Aldrich) at a final 
concentration of 3ug/ml at 37oC for 30 minutes. De-crosslinking and Proteinase K digestion 
were carried out simultaneously in elution buffer (20mM Tris-HCl, pH 7.5, 5mM EDTA, 50mM 
NaCl, 1% SDS, 20mM sodium-butyrate, 50ug/ml Proteinase K) for 65oC for 3 hours on a 
Thermomixer heatblock (Eppendorf) at 1300RPM. Immunoprecipitated chromatin was eluted 
into 500ul of elution buffer, and mixed with 500ul phenol-chloroform-isoamylalcohol, and 
separated by spinning down at 12,000g for 15minutes at room temperature. The aqueous layer 
was removed (about 450ul), mixed with an equal amount of isopropanol, 50ul of 3.0M pH 5.2 
sodium acetate and 5ul of GlycoBlue coprecipitant (ThermoFisherScientific) and mixed well by 
vortexing. Samples were incubated at -20oC overnight to precipitate DNA. Tubes were then 
thawed briefly on the counter, and spun down at maximum speed for 25 minutes at 4oC to pellet 
DNA. DNA was washed with 70% ethanol twice, and pelleted at maximum speed, 10 minutes, 
4oC. The DNA pellet was resuspended in 50ul of TE buffer, and further purified with a MinElute 
PCR purification kit (Qiagen), and eluted into 16ul of elution buffer. DNA was quantified, and an 
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equal amount of DNA for both input and immunoprecipitated samples were used for library 
preparation through the sequential steps of end repair (End-It DNA End-Repair Kit, Epicentre 
Biotechnologies), A-base addition (New England Biolabs), and adaptor ligation with T4 DNA 
ligase (Enzymatics, Qiagen). Libraries were purified with AMPure XP Beads (Beckman Coulter), 
subjected to 5 cycles of amplification to convert Y shaped adapters to DNA, and size-selected 
for 200bp-500bp fragments using the E-gel Size-Select system (Invitrogen). Size-selected 
libraries were then amplified for another 5 cycles, purified with AMPure beads to remove 
adapter dimers, and assessed for purity on the Bioanalyzer. Equal amounts of barcoded 
libraries were pooled and sequenced on a HiSeq4000.  
 
Short reads (50bp, single end) were aligned to hg19 using Bowtie2 with the following conditions: 
-p 10 -q -D 15 -R 10 -L 22 -i S,1,1.15, after adapter removal with fastq-mcf. Reads were filtered 
for mapq ≥ 30, and deduplicated, sorted and indexed with samtools. To generate bigwig files, 
tag density was first calculated by determining the midpoint of tags, and mapping them to within 
75 bp of each 20bp genomic bin for both input and immunoprecipitated samples. Blacklist 
regions were also removed using known regions from the ENCODE consortium using the 
bedtools –overlap function. Tag counts were normalized to library size, and input counts were 
subtracted before conversion into the bigwig format for viewing in IGV browser.  
 
 
3.9 Identification of superenhancers (SEs) and transcriptional enhancers (TE) and 
comparison of enhancers with DESeq2 
To identify H3K27ac peaks, we utilized MACS2 with the callpeak option, specifying the matched 
input sample as the control, and setting q<0.01. Peaks within 2kb of transcriptional start sites 
were removed, and peaks subsequently within 12.5kb of each other were stitched using the 
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ROSE algorithm (79, 80). Cumulative H3K27ac signal was determined for the stitched 
enhancers and ranked by H3K27ac signal strength in ascending order. When stitched enhancer 
rank and H3K27ac signal were plotted in a linear scatter plot and both axes scaled from 0 to 1, 
the point where the tangent of the curve is 1 was used as the cutoff for SEs and TEs. This was 
carried out for all biological replicates in each sample, and enhancers intersecting in all 
biological replicates were kept as representative enhancers for each sample type.   
 
In order to carry out principal component analyses and differential analysis, stitched enhancers 
across each sample type were merged into a masterlist using the bedops –merge function. 
Reads from both H3K27ac ChIPseq and ATACseq were then separately mapped to this 
masterlist with all stitched enhancers and utilized for DESeq2 analysis (v1.22.2) (118). To 
identify enhancers with statistically differences in signal intensities both sequencing datasets, 
data was normalized in DESeq2, before pairwise comparisons between all three populations 
were carried out. Differentially enriched SEs or TEs with FDR<0.05, log2 fold change>0.5 (fold 
change>1.5) were defined as cell-type specific regions and the rest categorized as common 
shared regions. Associated genes falling 3kb upstream or downstream were assigned to peak 
regions using the ChIPseeker package in R. Principal component analysis was carried out using 
the plotPCA function in DESeq2. Shared Treg-accessible enhancers were identified from 
pairwise comparisons of adult naïve against adult Treg samples that meet the cut-offs of 
FDR<0.05, fold change (FC)< -1.5 in both H3K27ac ChIPseq and ATACseq datasets. Shared 
Treg-inaccessible enhancers were similarly identified with FC>1.5. DESeq2 normalized reads 
mapping to shared enhancers were then utilized for plotting and statistical analysis. 
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3.10 Motif analysis for differentially expressed ATAC and H3K27ac peaks 
ATAC peaks were identified using MACS2 with the callpeak option and the following 
parameters: -f BAM --nomodel --shift 100 --extsize 200 -q .05. In order to make peaks 
comparable across all samples for differential enrichment analysis, peaks were merged across 
all samples using bedtools –merge function with the following parameters: -o distinct -d 100. 
Blacklist regions were also removed using known regions from the ENCODE consortium using 
the bedtools –overlap function. A similar merged peaklist was derived from H3K27ac peaks 
called by MACS2 as defined above.  To identify peaks with statistically differences in signal 
intensities both sequencing datasets, data was normalized in DESeq2, before pairwise 
comparisons between all three populations were carried out. Differentially enriched peaks 
FDR<0.05, log2 fold change>1.5 were defined as cell-type specific peaks and the rest 
categorized as common shared peaks. Associated genes falling 3kb upstream or downstream 
were assigned to peak regions using the ChIPseeker package in R. Treg-accessible peaks were 
identified from pairwise comparisons of adult naïve against adult Treg samples that meet the cut-
offs of FDR<0.05, log2FC>1.5 separately for H3K27ac ChIPseq and ATACseq datasets. Treg-
accessible peaks shared with fetal naïve T cells were defined as peaks that met the same FDR 
and FC cutoffs in the same directionality for adult naïve against fetal naïve T cell pairwise 
comparisons. Given the paucity of shared Treg—accessible peaks within the H3K27ac ChIPseq 
dataset, motif analysis was carried out on Treg-accessible peaks within the ATACseq dataset. 
Motif analysis was carried out using HOMER (Hypergeometric Optimization of Motif 
EnRichment) [cite] using findMotifsGenome.pl with –size 150. De novo motifs identified were 
replotted for publication quality in R using the ggseqlogo package[cite]. FOXP3 binding sites 
were obtained from a previously published FOXP3 ChIPseq dataset (GSE43119, [cite]). Overlap 
of FOXP3 binding sites with shared Treg-accessible peaks from both ATAC and H3K27ac 
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ChIPseq datasets within fetal naïve T cells was determined using bedtools –intersect with an 
overlap of at least 75%.  
 
3.11 Flow cytometry staining for Helios and activation markers in sorted naïve and Treg 
cells 
Sorted naïve and Treg cells from fetal and adult naïve T cells were incubated in FACS buffer with 
fluorochome-conjugated, anti-human surface mAbs. Fixation and permeabilization was 
performed using the Foxp3/Transcription Factor Staining Buffer set (Tonbo Biosciences) 
according to manufacturer’s instructions. Antibodies used include: CD25 FITC (2A3, BD 
Biosciences), Helios PE (22F6, Biolegend), FOXP3 PE (PCH101, ThermoFisher Scientific), 
CD31 PE (WM59, BD Biosciences), IgG1 kappa Isotype Control, PE (MOPC-21, BD 
Biosciences), CTLA4 PE-CF594 (BNI3, BD Biosciences), CCR4 PE-Cy7 (1G1, BD 
Biosciences), Ki-67 PE-Cy7 (B56, BD Biosciences), CD69 Alexa Fluor® 700 (FN50, Biolegend), 
FOXP3 eFluor660 (PCH101, ThermoFisher Scientific), Eos eFluor660 (ESB7C2, ThermoFisher 
Scientific), IgG2a kappa Isotype Control, eFluor660 (eBR2a, ThermoFisher Scientific) and CD4 
APC-H7 (L200, BD Biosciences). All cells were stained with a live/dead marker (GhostDye 
Violet 510; Tonbo Biosciences) to exclude dead cells from analysis. All data were acquired with 
an LSRII flow cytometer (BD Biosciences) and analyzed with FlowJo (TreeStar) software. 
Helios+ and Helios- gates were set based on the clearly positive and negative populations seen 
in adult Treg samples. Using this definition, all adult naïve T cell samples were observed to be 
fully within the Helios- population, and were subsequently used to define the Helios- gate for 
subsequent experiments as a biological negative control.  
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3.12 Treg induction assays  
Sorted adult or fetal naïve T cells were differentiated into Treg cells as detailed above with 
αCD3/αCD28/αCD2 tetramers (Stemcell Technologies) in the presence of exogenous IL-2 
(10ng/ml, Peprotech) and TGFβ (50ng/ml, Peprotech) according to the relevant experimental 
setup. For Treg induction in the presence of TGFβ blocking, 2.5μg/ml or 0.5μg/ml of neutralizing 
αTGFβ (1D11, R&D Biosystems) antibody was added to the culture medium where specified. 
Cells were cultured and harvested after 1, 3 and 5 days for analysis by flow cytometry. 100ul 
media changes were performed every two days starting from the first day of stimulation. Cells 
were stained, fixed and permeabilized as detailed above in flow cytometry staining. Additional 
antibodies used in analysis include: GARP PE-Cy7 (7B11, Biolegend), LAP BV421 (TW4-2F8, 
Biolegend), GITR BV421(108-17, Biolegend). All data were acquired with an LSRII flow 
cytometer (BD Biosciences) and analyzed with FlowJo (TreeStar) software.  
 
3.13 Methylation analysis of Treg-specific demethylated region (TSDR) in FOXP3 
conserved non-coding sequence 2 (CNS2) 
Methylation analysis of the FOXP3 CNS2 TSDR was carried out for ex vivo sorted adult naïve 
(n=4), fetal naïve (n=5), adult Treg (n=4) and fetal Treg (n=5) cells using the sort strategy defined 
in Supplementary Figure 1. iTreg populations were differentiated from fetal and adult naïve T 
cells, where they were harvested at Day 5 of differentiation, stained, fixed and permeabilized for 
FOXP3 and Helios staining as specified above. iTreg populations were sorted for FOXP3-, Helios-
FOXP3+ and Helios+FOXP3+ populations where relevant, as defined in Supplementary Figure 
11. All donors used for this analysis were confirmed to be male. To maintain parity across the 
whole analysis, ex vivo sorted naïve and Treg cells were also fixed and permeabilized before 
DNA extraction. DNA extraction for all fixed and permeabilized samples was carried out with a 
modified phenol-chloroform-isoamylalcohol extraction protocol. Briefly, 0.1x106 sorted cells were 
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resuspended in 400ul of lysis buffer (0.5% SDS, 50 mM Tris, pH 8, 10 mM EDTA), with the 
additional of 16ul 5M NaCl, and de-crosslinked overnight at 66oC in a heatblock. Elution was 
carried out the presence of RNAseA (10mg/ml, Sigma Aldrich) at 37oC for 1hr, before the 
addition of Proteinase K (20mg/ml, Sigma Aldrich) and further incubation at 45oC for another 
hour. Samples were then transferred into Phase Lock Gel tubes (Quanta Bio), and an equal 
amount of phenol-chloroform-isoamylalcohol was added. Tubes were inverted vigorously to mix, 
and centrifuged at maximum speed for 5 minutes. The aqueous layer was removed, mixed with 
an equal amount of isopropanol, 50ul of 3.0M pH 5.2 sodium acetate and 5ul of GlycoBlue 
coprecipitant (ThermoFisherScientific) and mixed well by vortexing. Samples were incubated at 
-80oC for 30 minutes, and then spun down at maximum speed for 30 minutes to precipitate 
DNA. The DNA pellet was carefully washed with 75% freshly prepared ethanol, and dried before 
resuspension in nuclease-free water for analysis. Methylation analysis was conducted by 
EpigenDx for human FOXP3 (ADS783-FS2). 
 
3.14 CRISPR-Cas9 editing reagents 
Single guide RNAs (gRNAs) were designed against exons in the Helios locus (IKZF2, 
NM_01620 transcript) using the online CHOPCHOPv2 webtool (119). Two independent gRNAs 
were selected – GGAGGAATCCGGCTTCCGAA (gRNA1, targets exon 4), 
GATACTACCAAGGCTCCTAA (gRNA2, targets exon 8).  crRNAs for each sequence and 
associated tracrRNA were chemically synthesized (Dharmacon), and were resuspended in 150 
mM KCl, 10 mM Tris pH 7.4 to generate 160uM stocks. A scrambled guide, 
GGTTCTTGACTACCGTAATT (NT) was also synthesized. A HDR template (HDRT) was also 
utilized to increase nucleofection efficiency (120). Synthesized HDRT (Dharmacon) was 
resuspended in 150 mM KCl, 10 mM Tris pH 7.4 to a concentration of 100uM. Purified Cas9-
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NLS at a concentration of 40uM, and stored in 20mM HEPES-KOH pH 7.5, 150mM KCl, 10% 
glycerol, 1mM DTT was obtained from Berkeley QB3 Macrolabs. 
 
3.15 CRISPR-Cas9 editing of the Helios locus 
CRISPR-Cas9 editing was carried out as previously detailed (121, 122). Cas9 gRNA 
ribonucleoproteins (RNPs) were assembled before experiments by assembling the gRNAs 
through incubating 160uM of crRNA with 160uM of tracrRNA (Dharmacon) at a 1:1 ratio for 30 
minutes at 37oC to a final concentration of 80uM. Assembled gRNAs are then subsequently 
incubated with 40uM of Cas9-NLS at a 1:1 ratio for 15 minutes at 37oC for a final concentration 
of 20uM RNPs. Nucleofection was performed using the Amaxa P3 Primary Cell 96-well 
Nucleofector kit and 4D-Nucleofector (Lonza). 1x105 sorted fetal naïve T cells per well were 
stimulated overnight in 96-well plates pre-coated with anti-CD3 antibodies (1ug/mL, HIT3a, BD 
Biosciences), and supplemented with soluble anti-CD28 antibodies (2ug/mL, CD28.2, BD 
Biosciences) and IL-2 (10ng/ml, Peprotech). Stimulated fetal naïve T cells were washed with 
PBS, and resuspended in 20ul of P3 solution. 5ul of the final 20uM RNP solution was added, 
along with 1ul of 100uM HDRT solution. Cells were gently mixed, and transferred to the 96-well 
shuttle device. Cells were electroporated using program EH-115 on the Amaxa 4D-Nucleofector 
(Lonza). 80ul of prewarmed culture media was added immediately post-nucleofection, and cells 
were allowed to recover for 15 minutes at 37oC. Nucleofected cells were then transferred into a 
96-well U-bottom plate, and additional culture media added to a final volume of 200ul. After 5 
hours, cells were spun down and 150ul of the culture media changed to increase cell viability 
and left to incubate overnight.  
 
Cells were stimulated the next day for Treg induction assays as detailed above, and harvested at 
Day 6 for analysis. Cells were fixed, permeabilized and stained with the following antibodies: 
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CD25 FITC (2A3, BD Biosciences), Helios PE (22F6, Biolegend), CTLA-4 (BNI3, BD 
Pharmingen), FOXP3 eFluor660 (PCH101, ThermoFisher Scientific) and CD4 APC-H7/BV650 
(L200, BD Biosciences). All cells were stained with a live/dead marker (GhostDye Violet 510; 
Tonbo Biosciences) to exclude dead cells from analysis. All data were acquired with an LSRII 
flow cytometer (BD Biosciences) and analyzed with FlowJo (TreeStar) software.  
 
Cells treated with NT and gRNA1/2 were reserved from some samples for DNA isolation to 
confirm editing at the Helios locus with Helios gRNAs. Up to 1x104 cells were resuspended in 
30ul of DNA QuickExtract solution. PCR primers spanning the predicted edited region were 
designed for each guide: 1) gRNA1_Forward: TCTCTTGCCCTGTTCAGAAGCA, 2) 
gRNA1_Reverse: ACCACTGCCACCCCTGAATAAA, 3) gRNA2_Forward: 
TGCCTGGATTCCACTGACTCAG, 4) gRNA2_Reverse: AAGGCCTAGTGGAATGTGTGCT. 
PCR was carried out using the Kapa HiFi PCR kit (Roche) according to manufacturer’s 
instructions. PCR amplicons were purified with MinElue PCR Purification kit (Qiagen) and 
Sanger sequencing carried out by MCLAB. Tracking of Indels by Decomposition (TIDE) online 
webtool (https://tide.deskgen.com) was utilize to align and compare sequences from the non-
edited sample against gRNA1/2-edited samples. Sequences were also visually checked using 
the ApE editor to assess for sequence abberations occurring immediately after the predicted cut 
site.  
 
3.16 RNA sequencing for HeliosKO and HeliosWT Treg populations 
CRISPR-Cas9 mediated Helios knockout in 6 biological replicates of fetal naïve T cells was 
performed as described above using Helios gRNA1 or the NT control guide for (all samples 
were all paired across nucleofection conditions). Cells were stimulated the next day for Treg 
induction assays as detailed above, and harvested at Day 6 for RNA extraction and analysis. 
112
RNA was extracted from 2.5x104 iTreg cells and purified with the Nucleospin XS RNA kit 
(Machery-Nagel) and assessed for quality by RNA Pico (Agilent Technologies). Ribosomal RNA 
was removed using the NEBNext® Poly(A) mRNA Magnetic Isolation Module (New England 
Biolabs), and library preparation was carried out using the NEBNext® Ultra™ II Directional RNA 
Library Prep Kit for Illumina®. Sequencing on a HiSeq4000 was carried out by the Center for 
Advanced core at University of California, San Franscisco. 50bp single-end reads were aligned 
to hg19 using Bowtie2, and read counts per gene were obtained using RSEM. The EdgeR 
package for Bioconductor (113, 114) was utilized to perform TMM normalization and differential 
expression analysis of samples.  Due to the multifactorial experimental design, a generalized 
linear model (gLM) design was specified: 
~Donor+Stimulation+Genotype+Stimulation:Genotype 
A blocking factor, Donor was added to adjust for differences between biological replicates taking 
into account the paired design. The design allowed for the assessment of the effect of 
stimulation condition (Stimulation: IL-2, IL-2 + TGFβ), whether Helios knockout was carried out 
(Genotype: Knockout, KO or wildtype, WT) and any possible interaction between the two 
factors. Negative binomial dispersion was estimated using the design specified, and genewise 
gLM was fit before likelihood ratio tests (LRTs) were utilized to determine differentially 
expressed genes. Given the low signal to noise ratio, we utilized a less stringent cut off to define 
differentially expressed genes as false discovery rate <0.05 and fold change>1.1 (FC). PCA 
analysis was carried out as detailed above. Three dimensional PCA plotting was carried out 
using the plotly package (v4.8.0).   
 
3.17 T cell restimulation and intracellular cytokine staining 
To assess IL-2 secretion after differentiation, fetal iTreg were re-stimulated with 1μg/ml Phorbol 
12-Myristate 13-Acetate (PMA, Santa Cruz Biotechnology), 1μg/ml ionomycin (EMD Millipore), 
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and 10ug/ml Brefeldin A (Sigma Aldrich) for 5 hours. Fetal iTreg were assessed at day 5 post 
stimulation; for cells which had previously undergone CRISPR-mediated editing, cells were 
analysed at D6. Unstimulated cells were used for gating controls. For analysis by flow 
cytometry, cells were washed, and then stained, fixed and permeabilized as described above. 
Antibodies used for staining were:  CD25 FITC (2A3, BD Biosciences), Helios PE (22F6, 
Biolegend), IL-2 PE/DazzleTM594 (MQ1-17H12, Biolegend), FOXP3 eFluor660 (PCH101, 
ThermoFisher Scientific), CD4 APC-H7 (L200, BD Biosciences). All cells were stained with a 
live/dead marker (GhostDye Violet 510; Tonbo Biosciences). 
 
3.18 Cytokine bead assays  
100ul of culture supernatant were collected at D3 and D5 of Treg differentiation with IL-2 only or 
in the presence of added TGFβ. Supernatants collected at D5 of Treg differentiation after 
CRISPR-Cas9 mediated Helios knockout were also analyzed. Supernatants were harvested and 
stored at -80oC prior to analysis. IL-10 (#558274) and IFNγ (#558269) concentrations were 
measured using the Cytokine Bead Assay (CBA) Flex kits (BD Biosciences) according to 
manufacturer’s instructions. 
 
3.19 Statistical analyses 
All statistical analyses were performed using R (cran.r-project.org, v3.5.2) and Bioconductor 
(www.bioconductor.org). Tests were specified with each experiment, p<0.05 level of confidence 
was accepted for statistical significance. Kruskal-Wallis test and Dunn’s post-test with 
Bonferroni correction was performed using the PMCMRplus (v1.4.1) package. Graphs were 
made using the ggplot2 (v3.1.0), ggrepel (v0.8.0) and cowplot (v0.9.4) R packages. Heatmaps 
were generated with the ComplexHeatmap (v1.12.0) R package.  
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3.20 Sequencing data availability  
ATACseq, H3K27ac ChIPseq and RNAseq raw and processed files are deposited in the Gene 
Expression Omnibus database under a superseries entry with the accession number 
GSE110472 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE110472). 
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CHAPTER 4 – FUTURE DIRECTIONS
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4.1 Evaluating the transition from a pro-tolerance immune system in utero towards 
sterilizing immunity in adulthood 
We show here that fetal naïve T cells are poised for Treg differentiation through their permissive 
Treg-biased transcriptional and epigenetic landscape, which is primed to synergize with TCR and 
cytokine signaling. This skewing towards immunotolerance generation upon antigen encounter 
is beneficial in utero, since most antigens encountered in the periphery will be self-antigens, 
non-inherited maternal antigens that have crossed the placenta (40), or possibly rare bacterial 
commensal antigens. However, this raises the question of how the fetal immune system 
transitions from favoring tolerance to generating the sterilizing, pro-inflammatory immunity 
required for life after birth, and whether this process is fully complete at the time of birth. 
Assessment of Treg proportions in preterm cord blood (the only current proxy for the human third 
trimester) in multiple studies indicated that preterm neonates had higher Treg percentages 
compared to term neonates (123) that was correlated with gestational age (124), and this was 
not altered regardless of the etiology of preterm labour (125, 126). Additionally, comparisons of 
Treg percentages within a pediatric cohort (<2 years) and a adult cohort (>25 years) showed that 
the pediatric samples consistently had increased Treg proportions ranging from 20-40% (127), 
which, barring different strategies in gating, is reminiscent of the increased Treg frequencies seen 
in fetal spleen and lymph node CD4+ T cell populations. This seems to suggest that the 
transition towards an “adult-like” immune system is incomplete at birth, and that the 
predisposition for Treg generation could be sustained through early childhood. This could be 
readily assessed by carrying out Treg differentiation in vitro for fetal, pediatric and adult naïve 
CD4+ T cells to evaluate if pediatric naïve T cells still give rise to higher proportions of iTreg cells 
than adults in both the absence and presence of TGFβ. Additionally, expression of the partial 
Treg-signature derived within this work could be used to correlate eventual iTreg differentiation 
potential with age. Lastly, the retention of increased Treg differentiation potential from birth into 
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childhood could have important implications for infection and vaccination, given that the 
differentiation of naïve T cells into pro-inflammatory effector Th cell subsets, rather than the re-
activation of memory cells, is presumably the primary T cell immune response generated in this 
age group. As such, Treg predisposition within pediatric naïve CD4 T cells could give rise to the 
increase susceptibility to viral and bacterial infections, as well as to ineffectual vaccine recall 
responses generated to childhood vaccines (51). Identification of the extent of this 
predisposition would be informative for the formulation of vaccines or approaches that can boost 
differentiation of naïve T cells towards pro-inflammatory Th subsets in newborn/pediatric 
patients.  
 
4.2 Identifying upstream environmental stimuli that “imprint” the fetal Treg-biased 
epigenome/transcriptome 
Since a partial Treg-biased epigenome and transcriptome is already present within fetal naïve T 
cells at steady state, future studies are needed to address the questions of what triggers the 
acquisition of these signatures in vivo, and whether this can be replicated in vitro. 
Transplantation of fetal hematopoietic stem/progenitor cells (HSPCs) into a SCID-hu Thy/Liv 
humanized mouse model generated CD4 single positive (SP) thymocytes that retained their 
capability for increased differentiation into FOXP3hiCD25hi Treg cells in vitro, and this was 
reflected in a larger fraction of FOXP3hiCD25hi cell in the CD4 SP compartment in vivo. The 
same changes were not observed in mice transplanted with adult HSPCs (41),indicating that 
acquisition of predisposition for fetal Treg differentiation can occur as early as the HSPC stage. 
Given that epigenetic imprinting in the HSPCs can be inherited in subsequent daughter 
populations, this raises a tantalizing proposition that differences in the fetal environment can 
already “imprint” a Treg-biased epigenome and transcriptome within the fetal HSPC population.  
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Multiple factors within the fetal environment in utero present ripe areas for investigation. One 
relevant observation is that members of the TGFβ family are enriched in fetal secondary 
lymphoid organs, consistent with the importance of TGFβ and its family members in the control 
of stemness, differentiation, proliferation and function of multiple cell types during development 
(128). Depletion of TGFβ family members in mice, particularly that of TGFβ2/3, result in 
developmental defects present in multiple organs at birth (128). Additionally, although we do not 
observe increased transcription of TGFβ1 within the secondary lymphoid organs (41), we show 
that fetal iTreg can potently upregulate GARP and LAP during differentiation, and have the 
machinery available to mediate the activation of bioactive TGFβ1. Further investigations are 
needed to clarify whether high concentrations of TGFβ family members are present at sites of 
HSPC development, whether fetal HSPCs already have expression of a transcriptional or 
epigenetic signature similar to that observed in fetal CD4+ naïve T cells, and which family 
members present could potentially drive “imprinting” of these signatures.  
 
Other candidates for consideration include the effect of the hypoxic environment in utero, as well 
as the presence of uniformly high concentrations of estrogen and progesterone throughout 
pregnancy. The role of hypoxia in Treg induction is complicated since parallel studies exist that 
implicate hypoxia and the subsequent upregulation of the HIF1α to predispose CD4+ T cell 
generation both towards a Th17 effector or Treg cell fate. Genetic deletion of HIF1α in two 
individual studies resulted in the failure to generate Th17 responses and a corresponding 
increase in FOXP3+ Treg proportions in mice (129, 130). In contrast, when HIF1α was stabilized 
by culture in vitro in hypoxic environments or in vivo within hypoxia-treated animals, an increase 
in Treg differentiation ability and abundance was observed, with no apparent effect on Th17 
effector differentiation (131, 132). Additionally, ablation of HIF1α specifically in Treg cells resulted 
in their failure to suppress effector T cell proliferation in vitro and colitis development in vivo 
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(132). As such the dosage, as well as the situation in which HIF1α is induced, seems to matter 
for whether Treg or Th17 cells are generated, given that full genetic ablation of HIF1α in the CD4 
compartment has drastic consequences on Th17 induction, while the stabilization of HIF1α via 
hypoxia is sufficient to favor Treg over Th17 conversion. Given that the fetus is present in the 
latter environment, it seem likely that HIF1α and other mediators activated by hypoxia might 
play an important role driving Treg differentiation over the Th17 phenotype. This can be clarified 
in future studies assessing the impact of hypoxia on Treg differentiation ability, as well as the 
acquisition of Treg transcriptional and epigenetic signatures, in adult and fetal naïve CD4+ T cells.  
 
Lastly, the pregnancy hormones progesterone and estrogen have been shown to have 
pleiotropic effects on effector Th and Treg differentiation and function (133). High levels of 
circulating progesterone and estrogen within the human fetus have been characterized, with 
both levels increasing rapidly from the early second trimester towards towards term (134). Both 
progesterone and estrogen have been shown to favor Treg differentiation in multiple parallel 
studies in mice (summarized in (133)). Of note, one study evaluating the effect of progesterone 
on human cord blood naïve T cells showed that progesterone could elicit Treg differentiation in 
the absence of exogenous TGFβ in a dosage-dependent manner, and that adult naïve T cells 
were resistant to the Treg-inducing effect of progesterone (135). This could point to long term 
transcriptional or epigenetic programming of fetal naïve T cells by progesterone (and estrogen) 
to favor Treg generation, and that the loss of progesterone exposure at fetal concentrations in 
adulthood result in the inability for Treg differentiation in response to progesterone signaling. 
More work is required to assess the effect of progesterone and estrogen on fetal Treg 
differentiation, and whether physiological levels found within fetal tissues are sufficient to 
program HSPCs towards the generation of progenitors that favor Treg differentiation.  
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4.3 Generating functional and stable Treg cell populations from naïve T cells in vitro 
Since their identification in the early 2000s, adoptive cellular transfer of Treg cells to initiate 
immunosuppression in autoimmune and inflammatory disease settings have already reached 
clinical trials in humans (136). The outsized ability of a small population of Treg cells to mediate 
immunosuppression in a antigen-specific as well as a non-specific manner through bystander 
activation make them an attractive target, as well as their ability for potential persistence, which 
will ensure enduring immunotolerance within the patient. Most of the current trials depend on the 
expansion of ex vivo Treg populations over a period of weeks, since a large infusion of Treg cells 
is needed for efficacy, and only ex vivo Treg cells retain the full demethylation of the FOXP3 
TSDR and by proxy, their stable immunosuppressive phenotype (136, 137). As such, the 
generation of iTreg cells from naïve T cell precursors, which are more abundant and easier to 
manipulate than ex vivo Treg cells, would be a strong alternative to Treg expansion in vitro.  
 
However, the use of iTreg cells in clinical settings have proven to be problematic since most iTreg 
cells have partial or absent demethylation at the FOXP3 TSDR, which results in instability upon 
re-transfer in vivo in preclinical mouse studies (38, 93). Furthermore, even though it has not 
been evaluated, it is likely that human adult iTreg cells do not acquire the epigenetic and 
transcriptional signatures present in ex vivo Treg populations that also ensure their phenotypic 
stability. We show here that human fetal naïve CD4+ T cells differentiate into iTreg cells that have 
phenotypic characteristics that are present in ex vivo human Treg cells that are not acquired by 
human adult iTreg cells, such as the repression of IL-2 and IFNγ secretion, and the ability to 
secrete IL-10 and produce and sequester latent TGFβ1. In the presence of TGFβ, almost all 
human fetal naïve T cells convert into FOXP3hiCD25hi iTreg cells, and they acquire a 
transcriptional signature only expressed by both fetal and adult ex vivo populations. Given that 
Treg differentiation ability might persist past time of birth, future studies into whether human cord 
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blood naïve T cells can recapitulate this effect in vitro will be important in bringing this closer to 
potential clinical application, since cord blood banks could serve as potential reserves for donor-
matched iTreg generation.    
 
In this study, we reveal that human fetal iTreg populations do not acquire demethylation at the 
FOXP3 TSDR regardless of whether Helios was expressed. We propose that this is due to the 
inability of TCR and TGFβ signaling in vitro to capture the complexity of Treg differentiation in 
vivo, since the input from multiple feed-forward loops likely contribute to full lineage 
commitment. DNA demethylation at the FOXP3 locus is governed by ten-eleven-translocation 
(TET) enzymes which mediate the oxidation of 5-methylcytosine during the process of 
demethylation (138, 139). Deletion of TET2/3 in mice then result in decreased Treg proportions in 
the periphery (138, 139), due to decreased stability of the Treg population as observed for 
FOXP3ΔCNS2-GFP mice (29). The use of vitamin C potentiates TET activity, and the addition of 
vitamin C during iTreg differentiation with TGFβ resulted in the a large drop in of 5-methylcytosine 
(5-MC) and 5-hydroxymethylcytosine (5-hMC) specifically at the FOXP3 CNS2 TSDR in mice 
(138, 139). This resulted in increased retention of FOXP3 in the differentiated vitamin C treated 
iTreg in vitro and in vivo (138, 139). Although the extent decrease in 5-MC and 5-hMC was not as 
apparent, the same effect of vitamin C on the stability of FOXP3 expression was observed in 
human adult iTreg differentiation (138), indicating that vitamin C could be used a potent co-factor 
to generate stable iTreg populations. It would be thus interesting to test if the addition of vitamin C 
to fetal iTreg differentiation would potentiate demethylation at the FOXP3 TSDR both in the 
absence or presence of TGFβ. Lastly, given that epigenetic modifications occur at other 
important Treg gene loci such as IKZF4, IL2RA, CTLA4 and TNFSRF18 (GITR), and precede 
FOXP3 expression, it will be important to evaluate if global modulation of histone modifications 
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can boost the acquisition of DNA demethylation patterns at the same underlying genes. Small 
molecule inhibitors to histone deactylase complexes (HDACs) are the most well characterized, 
and the use of HDAC inhibitors in mice have resulted in the increase FOXP3 Treg proportions as 
well as in their suppressive function (summarized in (140)). However, since the FOXP3 protein 
itself is stabilized itself by direct acetylation, it is difficult to ascertain if this effect is truly from 
modulation of the epigenome itself. Targeted histone modification via CRISPR activation 
(CRISPRa) could possibly be utilized to provide a more specific approach; it would be therefore 
interesting to assess if we could target fused dCas9 constructs with epigenetic modulators such 
as p300 to pre-identified enhancer regions to activate the Treg epigenome on a global scale. SE 
and TE regions identified within our work on the Treg epigenome identified here would be an 
important resource to inform guide RNA design and specificity in order to achieve appropriate 
activation only of Treg associated genes. 
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